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Summary 
 
Metastatic disease at distant sites is the main cause of death for patients of 
breast cancer. Among them, patients diagnosed with the subtype termed Triple 
Negative (TNBC) are affected the most by both residual disease after treatment 
and distant metastases. It is therefore of utmost importance to investigate more in 
depth the role of pathways related to TNBC development and metastasization, 
possibly identifying novel therapeutic or diagnostic targets. In this PhD project, 
the effect of the miRNome (i.e. known miRNAs encoded in the genome) was 
analysed on three pathways relevant for TNBC metastatic processes. A high-
throughput proteomic approach termed Reverse Phase Protein Arrays (RPPA) 
was exploited to quantify the effect of miRNAs on the expression of 62 proteins 
belonging to c-Met, Integrin, and WNT/β-catenin signalling pathways. Then, a 
novel network analysis method was developed, taking into consideration the role 
of the proteins within the pathway of interest, and therefore contextualising the 
miRNA:target interactions. miRNAs identified as modulators of WNT/β-catenin 
signalling were tested functionally by means of a reporter gene assay, 
characterising miR-193b, -409, -494-, and -92b as strong repressors of the 
pathway. Their ability to regulate proliferation was assessed in a context of 
pathway overactivation, revealing that miR-193b, -409, and -494 reduce it. 
Analysis of stem-associated surface markers CD44 and CD24 showed that miR-
193b is able to decrease the CD44+ population. Additionally, direct molecular 
interactions with predicted target sequences in 3’UTRs of mRNAs corresponding 
to the proteins probed were validated for miR-193b and miR-494. 
 
In summary, the findings of this dissertation describe the role of miRNAs as 
putative repressors or activators of metastatic pathways in TNBC, validating miR-
193b, miR-409, and miR-494 as highly integrated within the network of WNT/β-
catenin signalling. Furthermore, the RPPA results provide a useful resource 
available to the scientific community for further studies related to miRNA function 
in TNBC.  
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Zusammenfassung 
 
Metastasen in entfernten Organen sind die Haupttodesursache bei 
Bruskrebspatienten. Patienten, die mit dem triple-negativen Subtyp (TNBC) 
diagnostiziert wurden, sind nach der Behandlung am häufigsten von dem 
übriggebliebenen Tumor und von Fernmetastasen betroffen. Daher ist es von 
essentieller Bedeutung, die Rolle von Signalwegen im Zusammenhang mit der 
Entstehung von TNBC und dessen Metastasierung eingehend zu untersuchen 
und möglicherweise neue therapeutische oder diagnostische Möglichkeiten zu 
identifizieren. In dieser Dissertation wurde der Effekt vom miRNome (d.h. allen 
bekannten miRNAs) auf drei für TNBC-Metastasen relevante Signalwege 
untersucht. Die hochdurchsatz Proteom-Methode der sogenannten Reverse 
Phase Protein Arrays (RPPA) wurde genutzt um die Wirkung von miRNAs auf die 
Expression von 62 Proteinen, die zu den c-Met, Integrin und WNT/β-Catenin-
Signalwegen gehören, zu quantifizieren. Weiterhin wurde eine neue Methode für 
eine Netzwerkanalyse entwickelt, welche die Rolle der analysierten Proteine 
innerhalb des jeweilig fokussierten Signalweges berücksichtigt und somit miRNA-
Protein Interaktionen in den funktionellen Kontext setzt. miRNAs, welche als 
Modulatoren des WNT/β-Catenin-Signalweges eingeordnet worden sind, wurden 
durch einen Reportergen-Assay funktionell getestet, wodurch miR-193b, -409, -
494- und -92b als starke Repressoren des Signalweges charakterisiert worden 
sind. Ihre Fähigkeit die Proliferation zu regulieren wurde im Zusammenhang mit 
der Überaktivierung des Signalweges untersucht. Dies zeigte, dass miR-193b, -
409 und -494 die induzierte Überaktivierung des WNT/β-Catenin-Signalweges 
reduzieren. Die Analyse von Stammzell-assoziierten Oberflächenmarkern CD44 
und CD24 ergab, dass miR-193b in der Lage ist, die CD44+ Population zu 
verringern. Zusätzlich wurden direkte molekulare Wechselwirkungen von miR-
193b und miR-494 mit vorhergesagten Zielsequenzen in 3'UTRs von mRNAs 
validiert. 
 
Zusammengefasst beschreiben die Ergebnisse dieser Dissertation die 
funktionellen Rollen von miRNAs als putative Repressoren oder Aktivatoren von 
metastatischen Signalwegen in TNBC. miR-193b, miR-409 und miR-494 wurden 
als hochintegriert innerhalb des WNT/β-Catenin-Signalweges identifiziert. 
Darüber hinaus stellen die Ergebnisse der RPPA-Analyse einen umfangreichen 
Datensatz dar, der von der wissenschaftlichen Gemeinschaft für weitere Studien 
über miRNA-Funktionen im TNBC genutzt werden kann. 
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Abbreviations 
 
AU Arbitrary Units 
BC Breast Cancer 
BCA bicinchoninic acid assay  
BL2 Basal-Like 2 
BSA Bovine Serum Albumine 
DNA deoxyribonucleic acid 
ds double stranded 
EMT Epithelial to Mesenchymal Transition 
ER Estrogen Receptor 
EtOH Ethanol 
FBS Fetal Bovine Serum 
FC Fold Change 
FWD forward 
KD Knock Down 
KO Knock Out 
LF lipofectamine 
LumA Luminal A 
LumB Luminal B 
MBS miRNA Binding Site 
miRNA microRNA 
MSL Mesenchymal Stem-Like  
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells 
OE Over Expression 
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ON Over-night 
ORF Open Reading Frame 
PBS Phosphate-buffered saline 
PCR Polymerase Chain reaction 
PFA Paraformaldehyde 
PR Progesterone Receptor 
q-val q-value 
REV reverse 
RNA ribonucleic acid 
RPPA Reverse Phase Protein Array 
ss single stranded 
TGFβ Transforming Growth Factor β 
TNBC Triple Negative Breast Cancer 
TS TargetScan 
UTR Untranslated Region 
β-cat β-catenin 
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1. Introduction 
1.1. Breast cancer 
Breast cancer (BC) is the most diagnosed and the deadliest type of cancer in the 
female population worldwide, accounting for more than 1.6 million new cases and 
more than 500’000 deaths per year (Torre, Bray et al. 2015). Tumours of the 
breast tissue are highly heterogeneous and different subtypes with specific 
molecular and clinical features have now been identified. BC patients can be 
classified by immunohistological characteristics, such as expression of hormonal 
receptors (Oestrogen and/or Progesterone, ER/PR) or human epidermal growth 
factor 2 (ERBB2). Tumours which do not express any of these receptors are 
defined as Triple Negative Breast Cancers (TNBC) (Foulkes, Smith et al. 2010). 
With the advent of genomics, gene expression profiles of BC patients have been 
analysed and molecular ‘intrinsic’ subtypes defined by clusters of genes 
concordantly regulated. The five classes first proposed by Perou and colleagues 
are Luminal A, Luminal B, ERBB2+, Basal, and Normal Breast-like (Perou, Sorlie 
et al. 2000). These signatures could discriminate subtypes with distinct clinical 
outcomes, describing for the first time intrinsic differences in the biology of breast 
cancers (Sorlie, Perou et al. 2001) (fig. 1.1). 
 
 
 
Figure 1-1 Survival of patients classified by intrinsic molecular subtypes. Kaplan-
Meier curves describe the overall survival of a cohort of 72 patients with locally advanced 
cancer (Sorlie, Tibshirani et al. 2003). 
 
Although not with a complete overlap in classification, intrinsic molecular 
subtypes are correlated with the receptor status observed by 
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immunohistochemistry. Indeed, breast cancers of the luminal types display higher 
levels of ER and PR among the different tumour types, with the A type showing 
the highest expression. Luminal B subtype is instead characterized by a lower 
expression of ER and PR, and an increased expression of cell cycle-associated 
genes (CCNE1 and CCNB1), as well as proliferation-associated genes (MKI67) 
(Ades, Zardavas et al. 2014). The ERBB2+ subtype is characterized by 
amplification and/or overexpression of ERBB2, together with other genes found in 
the genomic area termed ERBB2 amplicon (17q22.24). The majority of basal-like 
tumours are triple negative at the histological level, as well as being positive for 
the Epidermal Growth Factor Receptor (EGFR) and cytokeratin 5 or 17 
(KRT5/17) (Sorlie 2004). 
 
The American National Cancer Institute releases every year statistics regarding 
breast cancer epidemiology in the United States. From this broad datasets it is 
possible to appreciate how in the US the 5-year survival of BC patients has 
dramatically increased since 1975, incrementing from 75.2% to a staggering 
89.7% for the years 2007-2013. The majority of patients greatly benefit from the 
early detection strategies that are now enacted in developed countries. This is 
not the case in low- and middle-income countries, indicating that easily 
accessible diagnostic strategies are needed to improve the survival rates. 
Despite the increase in survival in recent years, relative survival of women with 
distant metastases at diagnosis is still very low (26.9%) (SEER Cancer Stat 
Facts: Female Breast Cancer. National Cancer Institute. Bethesda, MD). 
Metastatic recurrent disease at distance sites remains the main cause of death 
for all breast cancer patients (Weigelt, Peterse et al. 2005), an extremely relevant 
issue for TNBC patients in particular. Indeed, they present the highest 
percentages in both local and distant recurrences, with metastases more 
common in brain and lungs (Lehmann, Jovanovic et al. 2016). As well, median 
duration of survival with distant metastasis is the lowest for TNBC (0.5 years) 
compared to other subtypes (2.2 for LumA, 1.6 LumB, 0.7 Her2+) (Kennecke, 
Yerushalmi et al. 2010).  
  
Patients affected by Luminal A/B or Her2+ tumours greatly benefit from an array 
of targeted therapies that have been developed in recent years. ER+ cancer 
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patients can be treated by endocrine therapies such as Tamoxifen or Fulvestrant, 
which affect the ER-dependent growth. For ERBB2+ patients, monoclonal 
antibodies aimed at the Her2 receptor are available (Trastuzumab and 
Pertuzumab), as well as dual kinase inhibitors that affect the downstream 
signalling (Lapatinib). Few (~5%) of TNBC patients present mutations in BRCA1 
or BRCA2 genes and can be effectively treated with PARP inhibitors (Robson, Im 
et al. 2017). However, for the majority of TNBC patients the only available 
treatments remain chemotherapy, either in adjuvant or neoadjuvant regimens. A 
promising novel target for TNBC tumours is EGFR, being overexpressed in 45-
70% of patients. However, recent reports of clinical trials with molecules available 
to inhibit EGFR at various levels of the signalling cascade have shown very poor 
results (Nakai, Hung et al. 2016). While ongoing trials test additional therapeutic 
combination to confirm or refute the importance of targeting EGFR in TNBC 
treatment, researchers approached additional pathways which could be active in 
parallel to EGFR to sustain tumour growth. The Hepatocyte Growth Factor (HGF) 
receptor c-Met is another RTK found overexpressed in a portion of TNBC 
patients, where it was additionally found associated to worse disease free 
survival when co-expressed with EGFR (Kim, Lee et al. 2013). Additionally, its 
overexpression and/or its activity (measured as phospho-c-Met) have been 
associated multiple times to worse overall survival and disease free survival 
regardless of the breast cancer subtype, hinting perhaps at a broader relevance 
for possible treatments options (Minuti and Landi 2015). 
 
1.2. Triple Negative Breast Cancer subtypes 
As already mentioned, TNBCs are defined histologically by the absence of 
expression of ER/PR/Her2 receptors, therefore representing a highly 
heterogeneous group of tumours within itself (Denkert, Liedtke et al. 2017). 
Indeed, patients classified as TNBC present different responses to 
chemotherapies, ranging from a pathological complete response associated with 
high rates of survival (30 to 40% of patients), to residual disease after 
neoadjuvant treatment, a prognostic factor of extremely poor survival. While few 
patients will not progress to metastatic disease within the first 3 year from 
diagnosis, the majority will instead recur during this time and have the worse 
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survival rate throughout the different breast cancer subtypes (Liedtke, Mazouni et 
al. 2008). 
 
Various attempts have been made to classify TNBC patients into distinct 
subtypes with clinical and intrinsic molecular characteristics, possibly stratifying 
them into groups which benefit or not from chemotherapy. In a study from the 
Pietenpol lab, data from 587 TNBC patients was extracted from 21 breast cancer 
publicly available datasets. Then, by unsupervised hierarchically clustering, six 
discrete subtypes were identified, each characterized by its specific gene 
expression profile. The resulting profiles were then analysed for pathway 
signatures, therefore identifying enrichment of specific signalling pathways in 
each subtype. The subtypes identified were Basal-Like1 and 2 (BL1 and BL2), 
Immunomodulatory (IM), mesenchymal (M), Luminal Androgen Receptor (LAR), 
and Mesenchymal Stem-Like (MSL). Additionally, by gene expression analysis, 
they classified the cell lines currently in use as TNBC models into the same six 
clinical subtypes, thus allowing researchers to choose experimental systems 
which hold a translational value. Indeed, this was proven in the study by targeted 
pharmacological inhibition of the pathways enriched in the subtypes (Lehmann, 
Bauer et al. 2011). The classification was refined in 2016 based on gene 
expression of micro-dissected tissues in order the remove the stromal and 
immune components. Indeed, the author showed that for some subtypes gene 
expression results were influenced by the non-tumour tissue, and therefore 
confounded the interpretation of the pathways relevant for the disease biology. 
Thanks to this analysis, IM and MSL signatures were identified as strongly 
dependent on the stromal cells gene expression. Therefore, the six subtypes 
were refined to four (BL1, BL2, M, and LAR) and patients previously classified as 
IM or MSL were reassigned. Further analyses of pathological complete response 
in the subtypes showed how BL2 and LAR display the lowest rates (0% and 10%, 
respectively). While LAR patients could benefit from anti-androgen receptor 
therapies which are under evaluation, BL2 patients face once again only the 
chemotherapeutic possibilities, with clear poor outcomes (Denkert, Liedtke et al. 
2017). 
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In summary, TNBC as a heterogeneous disease and the BL2 subtype specifically 
require deeper biological investigations to fully understand pathological 
mechanisms which underlie its clinical aggressiveness. In particular, due to the 
highest percentages in both local and distant recurrences and the lowest median 
survival with distant metastasis, these processes remain seminal to examine. 
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1.3. microRNAs: small non-coding regulators of gene expression 
microRNAs (miRNAs) are small (~22 nt. long), single stranded, non-coding RNA 
molecules that predominantly repress gene expression post-transcriptionally 
upon binding to 3’ untranslated regions (UTRs) of target messenger RNAs 
(mRNAs). Since their first discovery in C.elegans, they have now been found 
encoded in eukaryotic genomes, such as the ones of plants, animals, and 
protists, as well as in viral genomes. Published miRNA sequences and 
annotation are listed in the database miRBase. Its latest release (v. 21, from June 
2014) contains information for 28’645 genomic miRNA loci which giving rise to 
almost 36’000 mature sequences across all the organisms characterized 
(Kozomara and Griffiths-Jones 2014). 
 
In Homo sapiens (GRCh38 genome assembly), 1881 precursors and 2588 
mature miRNA sequences have been described, either experimentally or 
predicted by high homology with miRNAs discovered in other species. Analysis of 
conserved miRNA binding sites on 3’UTRs of human protein-coding transcript 
estimated that more than 60% of them are under selective pressure to maintain 
miRNA binding sites (Friedman, Farh et al. 2009). This widespread effect places 
miRNAs as regulators of virtually any biological process present in human 
development, physiology, as well as pathology (Ameres and Zamore 2013). 
 
1.3.1. miRNA biogenesis in animals 
miRNAs have been found located in diverse genomic contexts, encoded as 
single or polycistronic units. The majority of miRNA genes are positioned in 
intronic portions of both coding and non-coding transcripts, while few have been 
characterized in exonic regions as well. They are transcribed as long sequences 
(often more than 1kB) termed primary miRNA (pri-miRNA), containing local stem-
loop structures that comprise the mature miRNAs. Their transcription is mainly 
mediated by RNA polymerase II (RNA Pol II) under the control of RNA pol II-
associated transcriptional regulators. As for other RNA pol II-dependent genes, 
their transcription can be controlled by epigenetic modifications and specific 
transcription factors. 
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The pri-miRNA is processed in the nucleus by the microprocessor complex, 
comprised of the enzyme Drosha, an RNase III-type endonuclease, and its 
essential co-factor DGCR8. The complex recognizes the pri-miRNA and cleaves 
the stem-loop roughly 11 nt. away from the basal junction between ssRNA and 
dsRNA portion, releasing a hairpin ~65 nt. long, termed precursor miRNA (pre-
miRNA) (fig 1.2). 
 
The pre-miRNA is transported via the protein exportin 5 (EXP5) from the nucleus 
into the cytoplasm, where it undergoes another round of endonucleoytic 
cleavage. The RNase Dicer is the main effector of this process. Thanks to its 
“molecular ruler” structure, it is able to cut the pre-miRNA terminal loop, 
generating a double stranded RNA molecule which is roughly 22 nt. long. This 
step is frequently facilitated by dsRNA biding proteins (dsRBP) such as Tar RNA 
Binding Protein (TRBP) or PACT (also termed PRKRA). However, their presence 
doesn’t seem necessary for pre-miRNA processing, since purified Dicer was 
found to be functional in vitro even when uncoupled from these dsRBPs. 
 
This short RNA duplex is subsequently loaded onto an Argonaute protein (AGO1-
4), where the two strands are separated. Upon unwinding, only one of the two 
strands is retained onto Ago to form the miRNA-Induced Silencing Complex 
(miRISC). Analysis of preferential strand loading has demonstrated that the 
strand with the relatively least stable 5’ end is selected as a ‘guide’ and remains 
loaded, while the other strand, termed ‘passenger’ is promptly degraded. In few 
cases the selection seems dependent on the context, as both arms of the miRNA 
can be found expressed in different cellular settings (fig 1.3). 
 
Dissertation  Chiara Giacomelli 
 
 
 
20 
 
Figure 1-2 microRNA transcription an nuclear processing. A) miRNA genes are 
transcribed by RNA pol II into long pri-miRNA transcripts which are processed by the 
microprocessor into pre-miRNAs, which in turn are exported into the cytoplasm. B) 
Known mechanisms and modifications that regulate nuclear processing. (Figure from Ha 
and Kim, 2014, Nat Rev Mol Cell Biol) 
 
Both nuclear and cytoplasmic biogenesis steps have been studied in depth to 
identify possible regulators of these processes. Multiple post-translational 
modifications of the enzymes, as well as pri-/pre-/mature miRNA sequence 
alterations have been identified and are outlined in figures 1.2 (nuclear) and 1.3 
(cytoplasmic). This plethora of mechanisms indicates how the biogenesis of 
miRNAs is a tightly controlled process, potentially coupling external stimuli as 
well as intrinsic cellular conditions to the abundance of miRNAs, in general, as 
well as for specific ones. (Ha and Kim 2014) 
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Figure 1-3 Cytoplasmic processing of miRNAs. A) exported pre-miRNA is 
processed by Dicer and helper proteins such as TRBP. The small dsRNA is 
released and loaded onto an AGO protein which unwinds the duplex with the help 
of HSP90/HSC70. The mature miRISC is ready to regulate target genes. B) 
Known mechanisms and modifications that regulate cytoplasmic miRNA 
processing. (Figure from Ha and Kim, 2014, Nat Rev Mol Cell Biol) 
 
1.3.2. miRNA function in mammals 
Upon incorporation in the RISC, the mature miRNA guides the silencing complex 
to the target mRNA by base pairing with sequences present in its 3’UTR. The 
majority of binding sites is characterized by a full complementarity to the miRNA 
‘seed’ only (nt. 2-7). Various miRNA binding sites (MBS) with different affinities 
and efficacies have been described in literature. The most common ones are 
presented in figure 1.4 and are termed canonical (Baek, Villen et al. 2008). 
microRNAs that share the same seed sequence are considered members of a 
miRNA family, typically named after the first miRNA discovered which displays 
Dissertation  Chiara Giacomelli 
 
 
 
22 
that specific seed. Due to the fact that the seed sequence is the major 
determinant of the interactions with a target, miRNAs within a family share a 
subset of target genes. The context of the miRNA binding site in the 3’UTR has 
been described to influence the repressing capabilities of a miRNA-target 
interaction, further increasing the complexity of gene expression regulation 
possibilities (Bartel 2009). 
 
 
Figure 1-4 Schematic representation of the most commonly predicted miRNA 
binding sites. miRNA is depicted on the bottom in 3’ to 5’ direction with its seed 
sequence in purple. Predicted miRNA binding sites (seed matches) are depicted 5’ to 3’ 
sequences, color-coded according to seed match type (Baek, Villen et al. 2008). 
 
miRISC-mediated silencing of the target has been widely investigated in the past 
20 years with both in vitro and in vivo approaches to identify all the proteins that 
contribute to this mechanism. However, the precise spatial and temporal 
resolution of the events that lead to silencing is still under examination. Upon 
miRISC binding, silencing occurs as a combination of translational repression 
and mRNA processing and degradation. The predominant effect, as observed in 
multiple steady state in vitro experiments, is the degradation of the message, 
accounting for 2/3 and up to more than 90% of the final outcome on protein 
production. To achieve mRNA destabilization and subsequent exonucleolytic 
decay, AGOs proteins recruit GW182 proteins which further interact with 
downstream effectors such as the poly(A)-binding protein complex (PABPC) and 
the cytoplasmic de-adenylase complexes PAN2-3 and CCR4-NOT. Upon de-
adenylation, target mRNAs are decapped and readily degraded by the major 
cytoplasmic 5’-to-3’ exoribonuclease XRN1 (fig. 1.5).  
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Figure 1-5 Proposed mechanisms of miRNA-mediated target gene silencing. The 
miRISC binds by partial complementarity to BS in the 3’UTR of target genes (1) and 
recruits GW182 proteins (2), which in turn interact with proteins inducing deadenylation 
of target mRNA (3-9). DDX6 might interact (10) with decapping enzymes as well (11-12) 
which remove the 5’ cap of target mRNA, allowing the initiation of 5’-to-3’ mRNA 
exonucelolytic process. All the numbered interactions are supported by experimental 
structures identified in X-ray crystallography or nuclear magnetic resonance (NMR) 
experiments. The scheme does not represent the translational inhibition effect caused by 
interactions with 5’cap-associated translation initiation factors (Jonas and Izaurralde 
2015) 
 
A proposed method by which miRISC induces translational repression is through 
interfering with the assembly and activity of the cap-associated eukaryotic 
initiation factor 4F (eIF4F), thus affecting translation at initiation. This process is 
currently considered as a minor effect that happens at early stage of the 
silencing, accounting only for 6-26% of the effect on endogenous targets in 
mammalian cells. However, it is important to highlight that the temporal resolution 
could be a key factor in understanding the flow of events which lead to an 
effective silencing of targets (Jonas and Izaurralde 2015). 
 
Cell culture-based analyses of miRNA-mediated effects have repeatedly shown 
very mild effects, both at the transcriptomic and proteomic level. These effects 
have been quantified in gain- and loss-of-function studies, where miRNAs were 
overexpressed (OE) or knocked-down (KD). Indeed, in a seminal study from the 
Bartel group, miR-124 OE followed by analysis of protein and mRNA expression 
revealed an average repression of -0.18 and -0.3 log2FC for transcript that 
contained at least one MBS in their 3’UTR. As well, genetic inactivation of 
specific miRNAs (e.g. miR-223 in mouse neutrophils) caused de-repression of 
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targets at a similar range, with mRNAs and proteins upregulated +0.15 and +0.2 
log2FC, respectively (Baek, Villen et al. 2008). These variations have been 
considered to fall within the range of stochastic fluctuations which can be found 
within a population of genetically identical cells, putting into question how a single 
microRNA can exert a significant biological function when it affects so mildly the 
expression of its targets (Ebert and Sharp 2012). 
 
1.3.3. miRNA involved in control of networks 
A possible answer to this conundrum lays in the presence of multiple targets of 
the same miRNA, for the concomitant repression (or de-repression) of many 
effectors which are functionally integrated in a pathway can have a profound 
phenotypical change. Additionally, a recent report analysed the changes of 
mRNA levels, as well as post-transcriptional and epigenetic modifications upon 
loss of miRNA activity by Dicer KO. The results suggested that the majority of the 
effects were observable already at the transcription level, suggesting that the 
main effect of miRNAs is on transcription factors which, in turn, affect 
downstream expression of target genes (Gosline, Gurtan et al. 2016). 
 
Various networks of interactions between signalling pathway components and 
microRNAs, as well as feedback and feedforward loops with transcription factors 
have now been characterized, putting miRNAs in the spotlight as strong players 
in the gene expression arena (Bracken, Scott et al. 2016). Due to their dose-
sensitivity nature, biological pathways require fine-tuned control of the signalling 
cascade. In this contexts, miRNAs may become pivotal regulators, thanks to their 
ability to direct the expression of multiple targets concomitantly (Inui, Martello et 
al. 2010). 
The role of miRNAs as combinatorial regulators of specific phenotypes has been 
described multiple times in vivo for the miR-17-92 cluster, a group of six miRNAs 
concordantly regulated in development and cancer. Dissection of the contribution 
of each miRNA to specific phenotypes revealed that within the cluster both 
specialization of functions and cooperation are present (Han, Vidigal et al. 2015).  
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Figure 1-6 miR-200 family members regulate actin cytoskeleton. Proteins 
belonging to the actin cytoskeleton KEGG map (hsa04810) are coloured based 
on the verified interactions found in starBase database (Yang et al, 2011, NAR). 
As indicated by the blue lines, the phenotypes regulated by this multiple targeting 
strategy include various processes downstream the Integrin and RTK signalling 
cascades (Bracken, Scott et al. 2016). 
 
Many interesting examples have shown cooperative features of a miRNA on 
multiple targets, both in physiological and cancer related settings. In adult mouse 
neurons, miR-128 controls expression of various ion channels and ERK2 
signalling. By controlling this wide network, miR-128 regulates neuronal 
excitability and its loss causes intensified motor activity and fatal epilepsy (Tan, 
Plotkin et al. 2013). The miR-200 family members are found expressed 
preferentially in the epithelial compartment compared to the mesenchymal one. In 
cancer, their loss has been widely associated with epithelial to mesenchymal 
transition (EMT), mostly by de-repressing the transcription factors ZEB1 and 
ZEB2. However, a broader investigation of direct targets of the five miRNAs 
belonging to this family revealed how they cumulatively target proteins involved in 
actin cytoskeleton remodelling, affecting invasion and invadopodia formation in 
MDA-MB-231 breast cancer cells (fig 1.6) (Bracken, Li et al. 2014). 
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1.3.4. miRNAs in cancer 
microRNA expression is globally dysregulated in cancer tissues compared to 
their normal counterpart, an aberration further enhanced when tumours are 
poorly differentiated (Lu, Getz et al. 2005). While few of the deregulated miRNAs 
are overexpressed and might act as bona fide oncogenes, the majority is broadly 
downregulated. Indeed, miRNA genes have been mapped to genomic areas that 
are frequently found altered in the cancer, for instance fragile sites, minimal 
regions for loss of heterozygosity, minimal amplicons, and common chromosomal 
breakpoint loci (Calin, Sevignani et al. 2004). These genetic factors might 
contribute to the general miRNA expression repression characteristic of tumour 
tissues. Additional mechanisms that have been characterized as potential 
causative agents are broad epigenetic alterations such as aberrant promoter 
DNA methylation (Lujambio, Calin et al. 2008) and loss of specific histone 
acetylation markers (Saito, Liang et al. 2006). In recent years, special attention 
has been paid to understand the contribution of enzymes and critical cofactors 
involved in miRNA biogenesis in this context. Patient data analysis showed both 
upregulation and downregulation of the enzymes, as well as somatic and 
germline mutations, being correlated with clinical parameters only occasionally. A 
high variability in prognosis and other clinical features was found depending on 
the type of cancer, thus suggesting that the expression of enzymes involved in 
miRNA biogenesis is not enough to explain the global expression repression. In 
depth analyses of other key players in the biogenesis processing, showed the 
involvement of DEAD box helicases DDX5 (p68) and DDX17 (p72) in nuclear 
processing deregulation, upon interacting with BRCA1 as well as p53 tumour 
suppressor. SMADs transducers of TGFβ and BMP signalling have also been 
shown to interact with DDX5 to promote miRNA processing. miRNA processing 
modulation via interaction with DDX17 was instead discovered for the Hippo 
pathway, correlating cell density to mature miRNA levels (Lin and Gregory 2015). 
To conclude, core components of the miRNA biogenesis machinery have also 
been investigated for post-translational modifications such as phosphorylation 
and acetylation (fig 1.1 and 1.2) (Ha and Kim 2014).  
 
Of note, the widespread repression of miRNA expression in cancer is similarly 
found in cell types which are maintaining a pluripotent or dedifferentiated state. In 
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developmental contexts, extensive repression occurs concomitantly with high 
expression levels of specific miRNAs, which then represent the majority of the 
population present in the cell milieu. For instance, in mouse ESCs, more than 
75% of the miRNA population expressed was found to be encoding miRNA 
belonging to only six genomic loci, with a clear preference for the miR-290-295 
cluster (~60% of the population expressed) (Marson, Levine et al. 2008). It has 
therefore been speculated that miRNA increased expression during development 
is necessary to canalise phenotypic decision, promoting lineage-specific 
functions or suppressing alternative fates. On the contrary, in the tumour context, 
the widespread reduction in miRNA expression causes derepression of multiple 
targets and therefore an increase in transcriptional noise. In turn, this allows 
cancer cells to be highly adaptable to a constantly changing tumour environment, 
therefore conferring them an “evolutionary” advantage (Ebert and Sharp 2012). 
 
1.3.5. Functional analysis of miRNA-mediated network regulation 
Common methods to investigate the functional role of a miRNA within a specific 
context are gain- or loss-of-function experiments, followed by quantitative 
approaches such reporter gene or phenotypic assays, as well as gene 
expression analysis. Previous members of the Molecular Genome Analysis 
division have exploited these kinds of methodologies to investigate miRNAs 
regulating NF-kB and EGFR signalling pathways in the context of breast cancer 
(Keklikoglou, Koerner et al. 2012, Uhlmann, Mannsperger et al. 2012). In order to 
identify which miRNAs control NF-kB signalling, a library of constructs was co-
transfected with a plasmid containing 3 consensuses NF-κB-binding sites 
upstream the firefly luciferase gene, functioning as reporter for the pathway 
activity. MicroRNA-520/373 family was identified as a potent repressor of NF-kB 
signalling and of the phenotypes dependent on its activation. Additionally, miR-
520/373 was characterized to repress TGFβ signalling, providing a bridge 
between the two pathways (Keklikoglou, Koerner et al. 2012). A different 
approach has been exploited to identify miRNAs affecting cell cycle through 
EGFR signalling regulation. Upon miRNA OE, protein expression was quantified 
with Reverse Phase Protein Arrays (RPPA). The data was used to build a 
regulatory network which provided the basis to infer which miRNAs are 
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modulating the cell cycle. Three miRNAs (-124, -147, and -193a-3p) were 
validated for their role as strong repressors of cell cycle (Uhlmann, Mannsperger 
et al. 2012). The advantages of techniques such as RPPA are the quantification 
at the protein level and the high sample content. While the latter is necessary to 
understand the function of many miRNAs within the same assay, the former 
allows the identification interactions more likely to be functional. Despite having 
been described that the majority of miRNA-mediated effects can already be 
evaluated at the mRNA level (Guo, Ingolia et al. 2010), the possibility to 
investigate the protein output should still be preferred. Indeed, various reports still 
show that the correlation between mRNA and protein expression is poor, with the 
ability of the former to explain roughly 40% of the variation of the latter (Vogel 
and Marcotte 2012). 
 
A very informative version of such assays combines both the gain- and the loss-
of-function to identify molecules that may act as phenotypic switches. This 
approach was recently exploited to characterize miRNAs regulating the stem cell 
phenotype. By quantifying the cells positive for aldehyde dehydrogenase (ALDH) 
enzymatic activity upon miRNA OE and KD, researchers identified miR-600 as a 
bimodal switch that regulates the stem cell fate (El Helou, Pinna et al. 2017). 
Another method to identify miRNA that holds a functional value which was 
broadly exploited in the past years encompasses the analysis of miRNA 
differential expression between experimental conditions. In silico target 
predictions of the differentially expressed miRNAs is then performed, and 
predicted targets are listed. Then an enrichment for pathways based on gene 
ontology repositories is performed and the function of the miRNA is inferred 
(Gusev, Schmittgen et al. 2007). It is important to note that this method and its 
derivatives have been criticized due to the intrinsic bias in the sets of genes 
which are predicted to be targets of miRNAs (Bleazard, Lamb et al. 2015). 
However, gene set enrichment analysis becomes extremely helpful when 
performed on genes that are differentially expressed upon miRNA OE or KD to 
identify pathways concordantly regulated or bona fide direct targets that present 
predicted MBS in their 3’UTR (van Dongen, Abreu-Goodger et al. 2008). 
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Phenotypic screenings and analyses of reporter gene activity upon miRNA OE or 
KD have the advantage of defining directly which ones have a function. However, 
to fully understand the mechanisms underlying phenotypes identified, they 
require the dissection of the intricate network of miRNA-target regulations. On the 
other hand, while giving more insight into the molecular mechanism, gene 
expression or protein quantifications analyses necessitate computational 
approaches to infer miRNA function, therefore relying on pathway enrichment 
tools or other modelling methods. 
 
In silico prediction of target genes and online repositories of validated miRNA-
target interaction come to aid to sharpen the focus on interesting candidates that 
might arise from high-throughput functional or genomic screens. However, it is 
important to highlight that predictions are unable to identify all miRNA:mRNA 
interactions. This is mostly due to the fact that the knowledge that we hold on 
target identification mechanisms is still incomplete. Therefore, false-positives and 
–negatives are to be expected among target prediction results, with one or the 
others predominantly present depending on the algorithm exploited (Riffo-
Campos, Riquelme et al. 2016). The most recent release (v7) of TargetScan, one 
of the predominant target prediction algorithm, is powered by the context++ 
model which is based on 14 variables pertinent to the miRNA:mRNA interaction 
under investigation (Agarwal, Bell et al. 2015). Its performance, evaluated on 
gene expression data (i.e. mRNA level), recognizes it as the most precise tool 
currently available. However, its high specificity might hinder non-conserved, 
rare, or non-canonical interactions that are anyway biologically relevant (Riffo-
Campos, Riquelme et al. 2016). 
This reinforces the idea that while prediction algorithms come in great aid in the 
possible identification of direct targets, and therefore of the precise molecular 
mechanism that underlies miRNA function, their results require experimental 
validation. 
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1.4. Aims of the PhD project 
Regardless of the advancements in recent years in breast cancer biology, the 
current predominant treatment option for TNBC patients remains chemotherapy, 
with dismal chances of survival upon recurrence. Additional studies of the 
biological mechanisms underlying the metastatic processes are therefore needed 
to improve the clinical management of this disease. 
microRNAs, characterised in recent years as modulators of gene expression, 
have been implicated in the metastasis formation process in various types of 
cancer. However, a systematic approach to assess their ability to regulate 
metastatic pathways had not been undertaken before. 
 
The main aim of this project was to identify miRNAs able to repress pathways 
related to metastasis formation in a cell model of Triple Negative Breast 
Cancer. 
 
To achieve this aim, the project focused on: 
a) Systematically characterise the effect of the miRNome on proteins 
belonging to the pathways of interest by means of a targeted high 
throughput proteomic approach (RPPA). 
b) Developing a novel network analysis method to infer the effect of 
miRNAs on the pathways from their ability to regulate the single proteins. 
c) Focusing on a single pathway, validate the miRNAs for their capability 
to repress its activity and phenotypes dependent on it. 
d) Analyse interactions between miRNAs and target mRNAs to validate the 
direct integration of miRNAs in the pathway. 
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2. Materials and methods 
2.1. Materials 
2.1.1. Instruments 
2470 microarray printing platform Aushon (Billerica, MA, USA) 
ABI Prism 7900HT Sequence Detection 
System 
Applied Biosystems (Foster City, USA) 
Bacterial incubator (37°C) Memmert (Schwabach, Germany) 
Cell culture hood HERA Safe Thermo Fisher Scientific (Waltham, USA) 
Cell culture incubator CO2 controlled Binder (Tuttlingen, Germany) 
Cell Observer Zeiss (Jena, Germany) 
Centrifuges Eppendorf AG (Hamburg, Germany) 
 
Heraeus Instruments (Hanau, Germany) 
DNA gel apparatus Renner GmbH (Germany) 
Flow Cytometer FACS Canto II Becton Dickinson (New Jersey, USA) 
Gel documentation system Herolab GmbH (Wiesloch, Germany) 
Infinite M200 microplate reader Tecan Group (Männedorf, Schweiz) 
LSM 780 confocal laser scanning microscope Zeiss (Jena, Germany) 
Nanodrop ND-1000 spectrophotometer Thermo Fisher Scientific (Waltham, USA) 
Odyssey Infrared Imaging System 
Li-Cor Biosciences GmbH (Bad Homburg, 
Germany) 
Olympus microscope Olympus (Tokyo, Japan) 
Protein Gel Apparatus MiniProtean II Bio-Rad (Hercules, USA) 
Shaking bacterial incubator (37°C) INFORS HT (Eisenbach, Germany) 
Spectrophotometer Nano Drop nd-1000 Thermo Fisher Scientific (Waltham, USA) 
Thermocycler Applied Biosystems (Foster City, USA) 
Thermomixer Eppendorf AG (Hamburg, Germany) 
Trans-Blot SD Semi-Dry Electrophoretic 
Transfer 
Bio-Rad (Hercules, USA) 
UV imager Vilber (Eberhardzell, Germany) 
Vortex mixer neoLab (Heidelberg, Germany) 
 
2.1.2.  Disposables 
1.5 mL micro centrifuge tube  Eppendorf AG (Hamburg, Germany) 
2 mL micro centrifuge tube  Eppendorf AG (Hamburg, Germany) 
4–20% Mini-PROTEAN® TGX™ Bio-Rad (Hercules, USA) 
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12 mm round coverslips VWR International 
10cm Ø Petri dish 
Techno Plastic Products (TPP) AG (Trasadingen, 
Switzerland) 
15mL conical tube  Becton Dickinson (New Jersey, USA) 
50mL conical tube  Becton Dickinson (New Jersey, USA) 
6-well plate, flat bottom, transparent  Nunc, Thermo Fisher Scientific (Waltham, USA) 
6-well plate, Ultra Low Attachment Costar (Corning, USA) 
12-well plate, flat bottom, transparent Nunc, Thermo Fisher Scientific (Waltham, USA) 
96-well plate, flat bottom, transparent  Becton Dickinson (New Jersey, USA) 
96-well plate, flat bottom, white  
Greiner Bio-One International GmbH (Kremsmünster, 
Austria) 
96-well plate, flat bottom, μCLEAR®, 
black  
Greiner Bio-One International GmbH (Kremsmünster, 
Austria) 
Adhesive Optically Clear Plate Seal  Thermo Fisher Scientific (Waltham, USA) 
Cell Culture Flasks, T-25, T-75, T-175  
Greiner Bio-One International GmbH (Kremsmünster, 
Austria) 
Cell Scraper  Corning (Corning, USA) 
Cryo vials 1.8mL  Nunc, Thermo Fisher Scientific (Waltham, USA) 
Filter tips, 10μL, 20μL, 100μL, 200μL, 
1000μL  
Neptune Scientific (San Diego, USA) 
Glass slides Thermo Fisher Scientific (Waltham, USA) 
Incubation chambers Metecon (Mannheim, Germany) 
Inoculation loops 10 μL Copan (California, USA) 
ONCYTE® AVID nitrocellulose coated 
sldies 
Grace Biolabs (Bend, OR, USA) 
PCR strips  
Steinbrenner Laborsysteme GmbH (Wiesenbach, 
Germany) 
PVDF membrane Immobilon-P  Merck Millipore (Darmstadt, Germany) 
Serological pipettes 2.5mL, 5mL, 
10mL, 25mL, 50ml  
Becton Dickinson (New Jersey, USA) 
Whatman 3 MM filter paper  GE Healthcare (Little Chalfont, United Kingdom) 
 
2.1.3. Chemicals and reagents 
4’,6-diamidino-2-phenylindole dihydrochloride 
(DAPI)  
Sigma-Aldrich (Saint-Louis, USA) 
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4× Roti Load  Carl Roth (Karlsruhe, Germany) 
Acetic acid Sigma-Aldrich (Saint-Louis, USA) 
Acrylamide/bisacrylamide 37.5:1  Carl Roth (Karlsruhe, Germany) 
Agarose  Carl Roth (Karlsruhe, Germany) 
Ammoniumperoxodisulfate (APS)  Sigma-Aldrich (Saint-Louis, USA) 
Ampicillin  Sigma-Aldrich (Saint-Louis, USA) 
Bacto-Agar  Roche Diagnostics (Mannheim, Germany) 
Biozym Sieve GP Agarose  Biozym (Hessisch Oldendorf, Germany) 
BSA  Sigma-Aldrich (Saint-Louis, USA) 
Calcein, AM Invitrogen (Carlsbad, USA) 
Coelenterazine  Sigma-Aldrich (Saint-Louis, USA) 
CoenzymeA  AppliChem (Darmstadt, Germany) 
Complete Mini Protease Inhibitor Roche (Penzberg, Germany) 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich (Saint-Louis, USA) 
DL-Dithiothreitol (DTT) Sigma-Aldrich (Saint-Louis, USA) 
D-luciferin  AppliChem (Darmstadt, Germany) 
EDTA  Sigma-Aldrich (Saint-Louis, USA) 
Ethanol  Sigma-Aldrich (Saint-Louis, USA) 
Ethidium bromide  Sigma-Aldrich (Saint-Louis, USA) 
Gelatin From Pig Skin, Oregon Green® 488 
Conjugate 
Invitrogen (Carlsbad, USA) 
Gelatin from porcine skin (clear) Sigma-Aldrich (Saint-Louis, USA) 
Glutaraldehyde Sigma-Aldrich (Saint-Louis, USA) 
Hoechst 33342, Trihydrochloride, Trihydrate Thermo Fisher Scientific (Waltham, USA) 
Isopropanol  
Greiner Bio-One International GmbH 
(Kremsmünster, Austria) 
Lithium Chloride (LiCl) Sigma-Aldrich (Saint-Louis, USA) 
Methanol  
Greiner Bio-One International GmbH 
(Kremsmünster, Austria) 
MgSO4 Sigma-Aldrich (Saint-Louis, USA) 
Midori Green Advance Nippon Genetics (Düren, Germany) 
NaOH  Sigma-Aldrich (Saint-Louis, USA) 
non-DEPC treated nuclease-free water  
Ambion, Thermo Fisher Scientific (Waltham, 
USA) 
PFA 16% W/V AQ VWR International (Darmstadt, Germany) 
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PhosSTOP Roche (Penzberg, Germany) 
poly-L-lysine Sigma-Aldrich (Saint-Louis, USA) 
ProLong® Gold antifade reagent Invitrogen (Carlsbad, USA) 
Rhodamin Phalloidin Thermo Fisher Scientific (Waltham, USA) 
Rockland Blocking Buffer for Fluorescent Western 
Blotting 
Rockland (Limerick, PA, USA) 
SDS  Carl Roth (Karlsruhe, Germany) 
SOC medium  Invitrogen (Carlsbad, USA) 
Sodium borohydride Sigma-Aldrich (Saint-Louis, USA) 
Sodium Chloride (NaCl)  VWR International (Darmstadt, Germany) 
Sodium Citrate Tribasic Dihydrate  AppliChem (Darmstadt, Germany) 
Sodium Fluoride (NaF) 0.5M Sigma-Aldrich (Saint-Louis, USA) 
Sodium Hydrogen Carbonate for cell culture 
(NaHCO3) 
AppliChem (Darmstadt, Germany) 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich (Saint-Louis, USA) 
TEMED  Carl Roth (Karlsruhe, Germany) 
Tricine  Carl Roth (Karlsruhe, Germany) 
Tris HCl  Sigma-Aldrich (Saint-Louis, USA) 
Tris-base  Sigma-Aldrich (Saint-Louis, USA) 
Triton X-100  Sigma-Aldrich (Saint-Louis, USA) 
Tryptone Carl Roth (Karlsruhe, Germany) 
Tween® 20  Sigma-Aldrich (Saint-Louis, USA) 
Yeast extract Gerbu (Wieblingen, Germany) 
 
 
 
2.1.4. Buffers 
FCF staining solution 0.005% FCF 
  30% EtOH 
  10% Glacial Acetic Acid 
  in ddH2O 
  
FCF destaining solution 30% EtOH 
  10% Glacial Acetic Acid 
  in ddH2O 
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Blocking buffer 1:1 Rockland Blocking buffer: TBS 
  5 mM Sodium Fluoride 
  1 mM Sodium Vanadate 
  
TBS-T (washing buffer) 50mM Tris 
  150mM NaCl 
  0.1% Tween20 (v/v) 
  in ddH2O 
  
4x running buffer 1.5 M Tris-HCl, pH to 8.8 
  
4x stacking buffer 0.5 M Tris-HCl, pH to 6.8 
  
Anode I 300 mM Tris 
  20% EtOH (v/v) 
  in ddH2O 
  
Anode II 25 mM Tris 
  20% EtOH (v/v) 
  in ddH2O 
  
Cathode 40 mM 6-aminocaproic acid 
  20% EtOH (v/v) 
  in ddH2O 
  
SDS page running buffer 25 mM Tris 
  14.41 g/l glycine 
  1% SDS (w/v) 
  in ddH2O 
  
1x Tris-acetate-EDTA (TAE) 40 mM Tris 
  20 mM acetic acid 
  1 mM EDTA 
  in ddH2O 
  
FACS assay buffer 2% FBS in PBS 
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2.1.5. Molecular biology reagents 
Deoxynucleoside Triphosphate (dNTPS)  PeqLab (Darmstadt, Germany) 
Lipofectamine2000® Invitrogen (Carlsbad, USA) 
M-PER Mammalian Protein Extraction 
Reagent 
Thermo Fisher Scientific (Waltham, 
USA) 
SsoAdvanced™ Universal SYBR® Green 
Supermix (2x) 
Bio-Rad (Hercules, USA) 
TaqMan® Fast Universal PCR Master Mix 
(2x)  
Applied Biosystems (Foster City, USA) TaqMan® MicroRNA Assays  
TaqMan™ Universal PCR Master Mix, no 
AmpErase™ UNG 
Universal Probe Library (UPL)  
Roche Diagnostics (Mannheim, 
Germany) 
 
2.1.6. Kits 
Unless otherwise stated, all kits were used according to manufacturer’s instruction. 
BCA Protein Assay Kit PierceTM Thermo Fisher Scientific (Waltham, USA) 
miRNeasy Mini kit  
Qiagen (Hilden, Germany) 
QiaPrep Spin Miniprep Kit  
NucleoBond® Xtra Midi 
Macherey-Nagel GmbH & Co. (Düren, 
Germany) 
QuikChange Lightning Site-Directed Mutagenesis Kit  
Agilent Technologies (Waldbronn, Germany) QuikChangeLightning MultiSite-Directed 
Mutagenesis kit 
RevertAid™ H Minus First Strand cDNA synthesis kit  
Fermentas, Thermo Fisher Scientific 
(Waltham, USA) 
TA-Cloning Kit  Invitrogen (Carlsbad, USA) 
TaqMan® MicroRNA Reverse Transcription Kit Applied Biosystems (Foster City, USA) 
Wizard® SV Gel and PCR Clean-Up System  Promega (Mannheim, Germany) 
 
2.1.7. Enzymes 
Phusion® Hot Start High-Fidelity DNA Polymerase  
Finnzymes, Thermo Fisher Scientific 
(Waltham, USA) 
T4 DNA ligase  NEB (Frankfurt, Germany) 
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AmpliTaq DNA Polymerase  Applied Biosystems (Foster City, USA) 
DreamTaq Polymerase Thermo Fisher Scientific (Waltham, USA) 
XhoI / NotI-HF / PmeI NEB (Frankfurt, Germany) 
 
2.1.8. Size markers and loading dyes 
Orange DNA Loading Dye (6X) 
Thermo Fisher Scientific (Waltham, 
USA) 
O'Range Ruler 200 bp 
O'Range Ruler 100+500 bp 
MassRuler Mix 
4× Roti Load  Carl Roth (Karlsruhe, Germany) 
Precision Plus Protein Standards Dual 
Color 
Bio-Rad (Hercules, USA) 
 
2.1.9. Cell culture: cell lines, media, and other reagents 
MDA-MB-231 (ATCC® HTB-26™) American Type Culture Collection (Manassas, VA, 
USA) MDA-MB-468 (ATCC® HTB-132™) 
 
Standard Medium Leibovitz-L15  
Gibco BRL (New York, USA) 
  10 % Fetal Bovine Serum  
  3 g/lt of NaHCO3 Applichem (Darmstadt, Germany) 
   
Mammosphere 
Growth Medium 
DMEM-F12 
Gibco BRL (New York, USA) 
 
1x B27 supplement 
  
20 ng/ml recombinant human basic 
FGF 
R&D systems (Minneapolis, MN, 
USA) 
  20 ng/ml recombinant EGF Corning (Corning, USA) 
  4 ug/ml Heparin sodium salt Sigma-Aldrich (Saint-Louis, USA) 
Mammosphere formation medium was prepared according to the work of Dontu and 
colleagues (Dontu, Abdallah et al. 2003). 
PBS 
Gibco BRL (New York, USA) 
OptiMEM 
0.25% Trypsin EDTA Solution 
Cell Dissociation Buffer, enzyme-
free 
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WNT-7a recombinant human 
Peprotech (Rocky Hill, NJ, USA) WNT-1 recombinant human 
WNT-3a recombinant mous 
iCRT 3 CalbioChem Merck (Darmstadt, Germany) 
iCRT 14 SCB 
 
2.1.10. Bacterial culture: strains and broth 
Subcloning Efficiency™ DH5α™ Competent 
Cells 
Thermo Fisher Scientific (Waltham, USA) 
XL10-Gold® Ultracompetent Cells  Agilent Technologies (Waldbronn, Germany) 
 
Lysogeny Broth (LB) 10g Bacto-Trypton 
  10g NaCl 
  5g yeast extract 
  to 1 lt with ddH2O, then autoclave 
  100 µg/ml Ampicillin 
For agar plates preparation, 6 gr of Bacto-Agar are dissolved in 400 ml of LB broth, and 
autoclaved. Prior to pouring, Amp is addedd to a final concentration of 100 µg/ml 
   
2.1.11. Antibodies 
RPPA and Western Blot 
Primary antibodies used for target protein detection in RPPA and WB. For RPPA, except 
when noted, antibodies were used in dilution 1:300 in Blocking Buffer Rockland:TBS. For 
WB, the last column indicates the dilution used. 
Companies from which the Ab were purchased are listed abbreviated as subsequent. 
Abcam Abcam (Cambridge, UK) 
BD BD Biosciences (Heidelberg, Germany) 
CST 
Cell Signaling Technology (Danvers, MA, 
USA) 
Epit Epitomics (Abcam - Cambridge, UK) 
HPA Human Protein Atlas (Sigma-Aldrich, Munich) 
Merck Millipore Merck (Darmstadt, Germany) 
RnD RnD systems Inc. (Minneapolis, MN, USA) 
SCB 
Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) 
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Sigma Sigma-Aldrich (Munich, Germany) 
 
Protein Abbreviation Gene ID AB ID 
company 
(abbr.) 
WB 
dilution 
AKT/PRKBA AKT1 BD 610860 BD 
 
PRKBB AKT2 CST 3063 CST 
 
APC APC CST 2504 CST 1:500 
B-raf BRAF CST 9434 CST 
 
CCND1 CCND1 CST 2926 CST 
 
CCND3 CCND3 CST 2936 CST 
 
E-Cadherin CDH1 CST 4065 CST 1:1000 
CDK2 CDK2 C5223 Sigma 
 
CDK4 CDK4 
2341-1 
(ab68266) 
Epit 
 
p27/Kip1 CDKN1B BD 610241 BD 
 
CrkII CRK CST 3492 CST 
 
CKI alpha CSNK1A1 CST 2655 CST 1:500 
CKI epsilon CSNK1E CST 12448 CST 1:1000 
CKII alpha1 CSNK2A1 CST 2656 CST 1:1000 
CKII β CSNK2B sc-12739 SCB 1:200 
β-CATENIN CTNNB1 CST 9562 CST 1:1000 
ICAT CTNNBIP1 ab129011 Abcam 1:1000 
DIAPH1 DIAPH1 CST 5486 CST 
 
DUSP6 DUSP6 
2138-1 
(ab76310) 
Epit 
 
Dishevelld 3 DVL3 CST 3218 CST 1:1000 
EGFR EGFR CST 2646 CST 
 
c-Fos FOS sc-7202 SCB 
 
GRB2 GRB2 CST 3972 CST 
 
GSK3B GSK3B CST 9315 CST 1:1000 
HRAS HRAS 05-516 Merck 
 
ILK ILK CST 3862 CST 
 
JUN JUN CST 9165 CST 
 
LRP5 LRP5 CST 5731 CST 1:1000 
LRP6 LRP6 CST 2560 CST 1:200 
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MEK1 MAP2K1 BD 610122 BD 
 
ERK2 (1:200 dil.) MAPK1 sc-81458 SCB 
 
p38 MAPK14 CST 9212 CST 
 
ERK1 MAPK3 AF1575 RnD 
 
JNK1 MAPK8 ab7949 Abcam 
 
HGFR MET CST 3148 CST 
 
FRAP1 MTOR CST 2972 CST 
 
PAK1 PAK1 CST 2602 CST 
 
PAK2 PAK2 
2247-1 
(ab76293) 
Epit 
 
PDK1 PDPK1 sc-7686 SCB 
 
PI3K alpha PIK3CA CST 4249 CST 
 
PI3Kβ PIK3CB ab32569 Abcam 
 
PLCG1 PLCG1 ab41433 Abcam 
 
MLCP PPP1CA sc-7482 SCB 
 
PKC alpha PRKCA CST 2056 CST 
 
PKC delta PRKCD CST 9616 CST 
 
PS-1 PSEN1 CST 3622 CST 1:200 
PTEN PTEN CST 9552 CST 
 
FAK1 PTK2 CST 3285 CST 
 
SHP-2 PTPN11 
1609-1 
(ab32159) 
Epit 
 
Paxillin PXN CST 2542 CST 
 
RAC1 RAC1 CST 2465 CST 
 
Rap1 alpha RAP1A ab124963 Abcam 
 
pRB RB1 CST 9309 CST 
 
RhoA RHOA CST 2117 CST 
 
p160ROCK ROCK1 CST 4035 CST 
 
p164 ROCK-2 ROCK2 HPA007459 HPA 
 
Axam2 SENP2 HPA029247 HPA 1:250 
SHC1 SHC1 CST 2432 CST 
 
SOS SOS1 CST 12409 CST 
 
SRC SRC CST 2123 CST 
 
STAT3 STAT3 BD 610190 BD 
 
p53 TP53 sc-126 SCB 
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For WB, an antibody against Actin (MP Biomed 69100) was used diluted 1:10’000 as 
normalizer. 
 
For RPPA target detection, secondary antibodies were diluted 1:8’000 in TBS-T, except 
for the Donkey α-Goat which was diluted 1:20’000. For WB, secondary antibodies were 
diluted 1:10’000. 
Host α-Antigen type label   
Goat α-Mouse F(ab')2 of IgG Alexa Fluor 680 
Invitrogen 
(Carlsbad, USA)  
Goat α-Rabbit F(ab')2 of IgG Alexa Fluor 680 
Donkey α-Goat IgG IgG Alexa Fluor 680 
 
FACS 
blocking agent Human TruStain 
FcX™ 
 
BioLegend (San Diego, CA, USA) anti-human CD24 Antibody APC 
Mouse IgG2a, κ Isotype Ctrl 
Antibody 
APC 
Anti-Human/Mouse CD44 PE 
eBioscience (San Diego, CA, USA) 
Rat IgG2b K Isotype Control PE 
 
Invadopodia formation 
Host α-Antigen type   dilution   
Rabbit α-TKS5 (M-
300) 
poly IgG sc-30122 1:300 SCB 
Goat α-Rabbit IgG Alexa Fluor 633 1:400 
Invitrogen (Carlsbad, 
USA) 
 
2.1.12. Plasmids 
pcDNA3.1 (+) Invitrogen (Carlsbad, California) 
psiCHECK2 Promega GmbH (Neckarau, Germany) 
 
2.1.13. Oligonucleotides 
miRNAs 
Individual microRNA mimics as well as the miRIDIAN® miRNA mimic library (based on 
miRBase v.10) were purchased from Dharmacon (Lafayette, CO, USA). The negative 
controls miRIDIAN® miRNA mimic control #1 and #2 were used for the experiments. 
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siRNAs 
siRNA against CTNNB1 (ID M-003482-00) were picked from an siRNA library against 
whole human genome. ON-TARGETplus Non-targeting Pool (D-001810-10) was used as 
negative control in the experiments. Both products were purchased from Dharmacon 
(Lafayette, CO, USA) 
Cloning primers 
Primers 5' → 3' sequence 
corresponding 
cloned area 
APC_UTR_TS_fw_partI TACTCGAGGAAGCGAGATTCCAAAACTG 
APC_CA1 
APC_UTR_TS_rev_partI ATGCGGCCGCAATAGATAAGTGCCAACGCA 
APC_UTR_TS_fw_partII TACTCGAGTGTAATAGCAATGCAAGCAG 
APC_CA2 
APC_UTR_TS_rev_partII ATGCGGCCGCGGAATATTTGGCCTGCTATC 
APC_UTR_TS_fw_partIII TACTCGAGTTAGTCAGGAGTTACGATGC 
APC_CA3 
APC_UTR_TS_rev_partIII ATGCGGCCGCTTACAGGAGCCACAGTCTA 
CDH1_FWD_XhoI_CA1 TACTCGAGATGAAAAGTGGGCTTGGAG 
CDH1 
CDH1_REV_NotI_CA1 TAGCGGCCGCCACCCACACATGTATACACT 
CSNK1A1_FWD_XhoI_CA1 TACTCGAGCAAAAGGGCACAGGAGCCAC 
CSNK1A1 
CSNK1A1_REV_NotI_CA1 TAGCGGCCGCACTCAAGCCTGGGCGACAGT 
CTNNB1_TS_FWD_XhoI TACTCGAGTCAGCTGGCCTGGTTTGATAC 
CTNNB1 
CTNNB1_TS_REV_NotI TAGCGGCCGCTCAGCAACTCTACAGGCCAAT 
CTNNBIP1_FWD_XhoI_CA1 TACTCGAGTTCAGACTGGCCCTTAAGCCA 
CTNNBIP1 
CTNNBIP1_REV_NotI_CA1 TAGCGGCCGCCCCACAGCTGACTGTCAGCT 
DVL3_ENST00000313143_fwd TACTCGAGCATTTTCTCACCTGGATAAAGC 
DVL3 
DVL3_ENST00000313143_rev2 ATGCGGCCGCTGTGATGAAGTAACCAGGAG 
GSK3B_ENST00000264235_fw
d_partI 
TACTCGAGCCAGCTGCACAGGAAAAACC 
GSK3B_CA1 
GSK3B_ENST00000264235_rev
_partI 
ATGCGGCCGCGGCAAACATAGTCCTTCAATT
CTCC 
GSK3B_ENST00000264235_fw
d_partII 
TACTCGAGAAAACAGCAGATTCTGGGAG 
GSK3B_CA2 
GSK3B_ENST00000264235_rev
_partII 
ATGCGGCCGCAAAACTGTCCCTTTCAGAGTT
G 
LRP6_ENST00000261349_fw_p
artI 
TACTCGAGATTTGGTTGAGATCTGGAGG 
LRP6_CA1 
LRP6_ENST00000261349_rev_
partI 
ATGCGGCCGCTCACAAAAGAGGCTTCCATTA 
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LRP6_ENST00000261349_fw_p
artII 
TACTCGAGTCTTTCTGGGGTAGATGAGA 
LRP6_CA2 
LRP6_ENST00000261349_rev_
partII 
ATGCGGCCGCCCACACATTTATTAAGAGCTG
AC 
LRP6_ENST00000261349_fw_p
artIII 
TACTCGAGAGTATGGATATGAGTGTGTTGA 
LRP6_CA3 
LRP6_ENST00000261349_rev_
partIII 
ATGCGGCCGCAGGGAAGTGAATAAGTGGAC 
PSEN1_ENST00000324501_fw
_partI 
TACTCGAGTGGGCTTGTTTTCTACTTTG 
PSEN_CA1 
PSEN1_ENST00000324501_rev
_partI 
ATGCGGCCGCTTCAAATTCTGAGCTACTGTG 
PSEN1_ENST00000324501_fw
_partIII 
TACTCGAGTCTGACTCCAAATGACTCAA 
PSEN_CA2 
PSEN1_ENST00000324501_rev
_partIII 
ATGCGGCCGCCTGACAAATACAGAAAATCTG
C 
 
qPCR primers 
Target gene 5' → 3' sequence 
UC.82- F GTGTTTAAATCAATCAACTGCAAAC 
UC.82- R TTCAGTGTGGGATCACAGTAGG 
CTNNB1 F TGTTCTTGAGTGAAGGACTGA 
CTNBB1 R AAAATCCAGCGTGGACAATGG 
GAPDH F CGACAGTCAGCCGCATCTT 
GAPDH R CCCCATGGTGTCTGAGCG 
 
Mutagenesis primers 
Gene area 
miRNA 
BS 
5' → 3' sequence 
FW
D/ 
REV 
LRP6_CA1 
193b_N
C 
GCCAGATAGCCTTCAGTTAACTAACATTTCGCGG
CCAACAAGTAAGA 
F 
  
TCTTACTTGTTGGCCGCGAAATGTTAGTTAACTGA
AGGCTATCTGGC 
R 
LRP6_CA2 494 CCAAGGGGGAAAATGAATAATGAGGCATTAGATT F 
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CCTTATATGC 
  
GCATATAAGGAATCTAATGCCTCATTATTCATTTT
CCCCCTTGG 
R 
 
193b 
TTAAAGTACATTTTAATCTAATATAGGCTGCTAATT
GGGGGAAGGGGCTTTGAGC 
F 
  
GCTCAAAGCCCCTTCCCCCAATTAGCAGCCTATA
TTAGATTAAAATGTACTTTAA 
R 
APC_CA2 193b 
 
 
 
position
1 
GATTTTTTTTAAAGCTAAAATGCTGCTAAATAAAA
GTGCTATGACTTGAGC 
F 
  
GCTCAAGTCATAGCACTTTTATTTAGCAGCATTTT
AGCTTTAAAAAAAATC 
R 
 
position
2 
AGTGGGGGGAGACGGGCTGCTCTATACTACCCA
TTG 
F 
  
CAATGGGTAGTATAGAGCAGCCCGTCTCCCCCCA
CT 
R 
PSEN1_C
A1 
494 
GCGGTTAGAATCCCATGGATGAGGCTTCTTTGAC
TATAACAAAATCTGGG 
F 
  
CCCAGATTTTGTTATAGTCAAAGAAGCCTCATCCA
TGGGATTCTAACCGC 
R 
 
193b 
 
 
 
position
1 
ATTGCCATTTCTTCCCAAGGCTGCTCTGAACCTG
AGGTTGCT 
F 
  
AGCAACCTCAGGTTCAGAGCAGCCTTGGGAAGA
AATGGCAAT 
R 
 
position 
2 
GCAGTCTTTTTCTACAGCTGCTAAGGCAGCTCTG
TCGTGGTAG 
F 
  
CTACCACGACAGAGCTGCCTTAGCAGCTGTAGAA
AAAGACTGC 
R 
DVL3 193b 
ACAGGAGCCCACAGGCTGCTTGAGGTTGGGCAA
GG 
F 
  
CCTTGCCCAACCTCAAGCAGCCTGTGGGCTCCT
GT 
R 
CTNNB1 193b 
GGTAAGAAGTTTTAAAAAGCTGCTTTGGGTAAAAT
ACTTTTACTCTGCCTACAG 
F 
  
CTGTAGGCAGAGTAAAAGTATTTTACCCAAAGCA R 
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GCTTTTTAAAACTTCTTACC 
CTNNBIP1 193b CTAGGTGCCCAGGGCTGCTGGGACCCTCTCAGA F 
  
TCTGAGAGGGTCCCAGCAGCCCTGGGCACCTAG R 
 
miRNA TaqMan primers 
mature miRNA 
TaqMan 
assay ID 
miRBase ID or target sequence 
hsa-miR-103a-3p 000439 MIMAT0000101 
hsa-miR-193b-3p 002367 MIMAT0002819 
hsa-miR-409-3p 002332 MIMAT0001639 
hsa-miR-494-3p 002365 MIMAT0002816 
hsa-miR-889-3p 002202 MIMAT0004921 
RNU44 001094 
CCTGGATGATGATAGCAAATGCTGACTGAACAT
GAAGGTCTTAATTAGCTCTAACTGACT 
HY3 001214 
CCAGTCACAGATTTCTTTGTTCCTTCTCCACTCC
CACTGCATCACTTAACTAGCCTT 
 
2.1.14. Databases and online resources 
Online databases and resources are listed together with the version used and the 
respective release years, when available. KEGG Pathway is continuously updated and 
therefore the year listed corresponds to the time when the database was queried to 
determine the targets of interest for the project. The year indicated is the release year for 
the version indicated. If no version is indicated, the year corresponds to the time when 
data used in the thesis was accessed. 
Database Vers Year Link 
miRBase 21 2014 http://www.miRBase.org  
ENSEMBL 89 2017 http://www.ensembl.org  
TargetScan 7 2015 http://www.targetscan.org/vert_71/ 
MicroCosm 
Targets 
5 2009 http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/# 
KEGG 
Pathway  
2013 http://www.genome.jp/kegg/pathway.html  
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Benchling 
 
2016 https://benchling.com/ 
miRTar Base 6 2015 http://mirtarbase.mbc.nctu.edu.tw/php/index.php 
TCGA data 
portal 
 2016 https://tcga-data.nci.nih.gov/docs/publications/tcga/ 
 
2.1.15. Software 
Commercial 
FACSDIVA™ Becton Dickinson (New Jersey, USA)  
GenePix Pro v7 Molecular Devices (Sunnyvale, USA) 
GraphPad Prism 
5  
GraphPad Software, Inc. (La Jolla, 
USA)  
ImageStudio v3.1 Li-Cor (Lincoln, USA)  
Odyssey 2.1  Li-Cor (Lincoln, USA)  
SDS 2.2  Applied Biosystems (Foster City, USA)  
ZEN blue Zeiss (Jena, Germany) 
  
Open Source 
Fiji (ImageJ) https://imagej.net/Fiji 
R https://cran.r-project.org/ 
TinnR v 2.4.1.7 https://sourceforge.net/projects/tinn-r/ 
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2.2. Methods 
2.2.1. Cell culture 
The human triple negative breast cancer cell lines MDA-MB-231 (231) and MDA-MB-468 
(468) were cultured in Leibovitz-L15 medium (Gibco, Thermo Fisher Scientific) 
supplemented with 10% Fetal Bovine Serum (Gibco). Leibovitz-L15 medium is 
formulated for culturing in environments without CO2 control. Therefore, in order to 
culture 231 and 468 cells in CO2 controlled incubators, the medium is supplied with 3 g/lt 
of NaHCO3. Cells were grown at 37ºC and 5% CO2. Cells were split every 3-4 days with 
a 1:3/1:4 ratio. Cells were obtained from ATCC (Manassas, VA, USA) at passage 2 (P2) 
and cultured to maximum P20 (231) and P10 (468). 
 
2.2.2. Generation and maintenance of Stable Isogenic Recombinant Cells 
(SiR cells) 
(performed by Dr. Rainer Will, Rita Schatten, and Birgit Kaiser of the Stable isogenic 
recombinant core facility, DKFZ, Heidelberg) 
A) Generation of the isogenic recombinant cell line 
MDA-MB-231 were generated as described in Wittig-Blaich S et al. (1) Briefly : A 
Mammalian expression vector (pPAR3) containing a Flp recombinase target site N-
terminally fused to EGFP under control of an elongation factor 1-alpha (E1Fα) promoter 
and  a neomycin selection marker, was stably integrated in the genome of MDA-MB-231 
cells.  Neomycin resistant and EGFP positive clones were isolated and further validated 
for single-copy integration of the FRT site by Southern blotting.  Functionality of the 
MDA-MB-231-pPAR3 acceptor cell line was further evaluated by a control Flp-mediated 
control recombination with either a Doxcylin inducible hcRED expression vector for visual 
testing or a red firefly expression vector for quantitative expression analysis. The 
carefully examined MDA-MB-231-pPAR3 acceptor cell line served a platform for the 
generation of isogenic variants. 
 
B) Generation of MDA-MB-231-pPAR3 WNT- Luciferase reporter cell lines and culturing 
For the generation of MDA-MB-231-pPAR3 WNT-Pathway cell lines a promoterless FRT 
expression vector containing a RNA polymerase II transcriptional pause signal from the 
human α2 globin gene followed by 6 repeats of the TCF/LEF transcriptional response 
element (AGATCAAAGGGGGTA) joined to a minimal TATA-box promoter and 
destabilized firefly luciferase reporter was “flipped in” the MDA-MB-231-pPAR3 acceptor 
cell line by cotransfection with a Flp recombinase expression vector (pOG44 / 
Invitrogen). After selection for hygromycin resistance (expression vector) and loss of 
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EGFP expression (positive integration events), single colonies were picked and analyzed 
with for WNT / luciferase responsiveness in the presence of recombinant WNT. 
Positive colonies were cultured in Leibovitz-L15/10%FBS/3gr/lt NaHCO3 supplemented 
with 400µg/ml hygromycin. 
 
2.2.3.  Transfections 
A) Transfections and protein extraction for RPPA screen (respectively performed by 
Stefan Uhlmann and Heiko Mannsperger, former PhD students, MGA Division, 
DKFZ, Heidelberg) 
The miRIDIAN miRNA mimic library from Dharmacon (corresponding to the miRBase 
database v10) was transfected in MDA-MB-231 cells with the help of the pipetting robot 
Biomek FX (Beckman Coulter, Krefeld, Germany). The miRNAs were transiently 
transfected at a final concentration of 25 nM. To transfect the whole library, the process 
was divided into 34 rounds. Negative controls #1 and #2 (Dharmacon) were transfected 
in every round. Cells were harvested by trypsinization 48 hrs. after transfection. Cell 
pellets were stored at -80ºC. 
Protein were extracted from the cell pellet with 25 ul of Mammalian Protein Extraction 
Reagent (M-PER, Pierce, Rockford, IL, USA), supplemented with Complete Mini Protase 
Inhibitor (Roche, Penzberg, Germany). Lysis was carried for 20’ at 4ºC on a shaker. 
Protein lysate was cleared by centrifugation at 13’000 rpm for 5’ and the supernatant 
was stored at -80ºC. 5 ul of the lysate were used to measure protein concentration using 
the BCA colorimetric kit. (Pierce, Rockford, IL, USA). Sample concentrations was 
adjusted (when possible) to similar concentration using M-PER buffer. Tween 20 (Sigma 
Aldrich, Munich, Germany) was added to each sample at a final concentration of 0.05% 
to reduce surface tension and render the RPPA spotting process smoother. Samples 
were loaded into 384-well plate for RPPA spotting, and subsequently stored at -80ºC. 
 
B) 6-well transfections  
231 and 468 cells were seeded at the density of 2x and 3x105 per well (respectively). 
The subsequent day, cells were transfected with 25 nM miRNA mimics and mimic 
controls (Dharmacon) or 20 nM siRNA and OnTarget plus siRNA control (Dharmacon). 
Transfection mixes per well were prepared as shown in the subsequent table. 
Mixes were incubated separately for 15’. Then they are combined 1:1 in a single tube 
and incubated for 20’. During incubation time, the medium in each well was removed and 
replaced carefully with 1ml of fresh medium. Then the transfection mix was distributed 
drop-wise on cells. With this procedure, there is no need to change the media after 6 hrs. 
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 ul x1 well 
LF 2000 4 
OptiMEM 246 
Tot vol mix1 250 
  
OptiMEM 248.5 
miRNA/siRNA (stock 25 
uM) 
1.5 
Tot vol mix2 250 
 
RNA and proteins were harvested 48 hrs post-transfection in at least 2 biological 
replicates to perform validation of RPPA results via Western Blot (WB), as well as to 
analyze gene and miRNA expression upon modulation of the WNT/β-catenin pathway.  
 
C) 96-well transfections for proliferation assays and WNT-reporter luciferase assays. 
231 cells were plated at a density of 5x104 in 96-well plates. The subsequent day cells 
were transfected with 25 nM microRNA mimics or mimic controls with the subsequent 
mixes. 
 
ul x1 well 
OptiMEM 49.6 
Lipof2000 0.4 
Tot vol mix 1 50 
  
Optimem 49.9 
miRNA (stock 25 uM) 0.1 
Tot vol mix 2 50 
 
Mix 1 and mix 2 were incubated separately for 10’. Mix 1 was prepared in amount to be 
used with all the different miRNA or control conditions. Subsequently the two mixes were 
combined 1:1 in a new tube and incubated for 20’. Afterwards, the medium was removed 
from the wells, and 100 ul of the transfection mix were distributed with a multichannel 
pipet. 6-7 hrs after transfection, the mix was removed and replaced by 150 ul of fresh full 
medium. 
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D) 96-well transfections for 3’UTR reporter assays 
231 cells were plated at a density 1x105 per well in 96-well plates. 
The subsequent day cells were transfected with 25 nM microRNA mimics or mimic 
controls and 50 ng of reporter plasmid per well. 
The mixes were prepared in order to have a unique Lipofectamine+OptiMEM mix (Mix1) 
for all the wells, as well as the same miRNA+OptiMEM mix (Mix2) for assay uniformity. 
As a consequence, a single mix1 is then combined with appropriate plasmid (sub-mix1), 
which is then distributed in tubes containing the mix2. 
 
Prior all assays, the reporter plasmids were diluted to 1ug/ul to streamline the process. In 
few cases the reporter plasmids were not concentrated enough after midiprep and 
therefore not diluted. 
 
 
 
ul x1 
well 
Sub-mix1 
addition 
OptiMEM 50  
Lipof2000 0.4  
Tot vol mix 1 50  
Plasmid (1000ng/ul)  0.05 
   
Optimem 49.9  
miRNA (stock 25 uM) 0.1  
Tot vol mix 2 50  
 
Mix 1 is prepared and incubated for 20’. In the meantime, mix 2 is prepared and 
distribute into a deepwell plate. 
Then, the appropriate volume of mix1 is mixed with plasmid and then distributed into the 
deepwell plate containing the mix2. For each vector, transfection was performed with 2 
miRNA controls, miRNAs of interest, and a mock mix. After 20’ of incubation the medium 
was removed from the wells, and 100 ul of the transfection mix were distributed with a 
multichannel pipet. 6-7 hrs after transfection, the mix was removed and replaced by 150 
ul of fresh full medium. 
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2.2.4. Reverse Phase Protein Array (RPPA) 
Cell lysates frozen in 384-well plates prepared by Stefan Uhlmann and Heiko 
Mannsperger were thawn on ice. The lysates were spotted on nitrocellulose-coated glass 
slides (Grace Biolabs, Bend, OR, USA) using the Aushon 2470 contact printer (Aushon, 
MA, USA). The samples were divided into 4 groups, termed arrays (AI, AII, AIII, and 
AIV), which were spotted independently. In each of the group, two dilution series of 
untreated 231 cells and two series of mock-transfected 231 cell lysates were spotted to 
allow proper quality control. 
Printed slides were allowed to dry overnight at room temperature, and then stored at -
20ºC in sealed plastic bags containing silica gel beads to reduce at minimum the 
humidity and therefore decrease the formation of ice crystals which could damage the 
spotted proteins. 
 
Printed slides were secured in 2-pad incubation chambers and blocked for 2 hrs at room 
temperature with 2 ml/pad of Blocking Buffer. Subsequently, they were incubated O.N. at 
4ºC on a rocking platform with highly specific primary antibodies diluted in Blocking 
buffer at 1:300 (unless otherwise stated). The subsequent day, slides were washed 4x 
with 2.5 ml/pad of Washing buffer, then incubated for 1h at RT with Alexa Fluor 680 
F(ab’)2 fragments of goat anti-mouse immunoglobulin G (IgG) or anti-rabbit IgG (Life 
Technologies). Secondary antibodies were diluted 1:8’000 in Washing buffer (unless 
otherwise stated). Slides were then washed 4x with 2.5 ml/pad of washing buffer. The 
incubation chambers were then unmounted and slides were washed 2x with milliQ H2O 
and allowed to dry for 30’ at RT. 
To confirm specificity of Ab detection, some pads were incubated only with the 
secondary Ab and were termed as blank. 
One every 9 slides (corresponding to slide #5 for every tray) was stained with Fast 
Green FCF to detect the total protein content of each spot. Each slide was quickly made 
wet with PBS, which was then removed. Then, slides were stained for 45’ at RT on a 
rocking platform with FCF staining buffer. Afterwards, slides were washed 2x for 15’ with 
destaining buffer. Then, 2x for 5’ with milliQ water, and allowed to dry at RT for at least 
30’. Staining was performed in specific cassettes to avoid contaminating the incubation 
chambers with FCF which would lead to unspecific staining. 
 
The slides were scanned at high resolution (21 um) using a 700 nm wavelength on an 
Odyssey scanner (LI‐COR, NE, USA). The images were numbered according to the 
group of samples (AI, AII, AIII, and AIV), the slide printed (s1 to s9), the tray number they 
belong (t1 to t8). 
Dissertation  Chiara Giacomelli 
 
 
 
52 
 
Signal intensities were extracted from the images using the GenePix Pro 7 software 
(Molecular Devices, CA, USA) and saved as .gpr files with the same naming as the 
image and the definition of the top or bottom array with the _T or _B suffix. 
2.2.5. RPPA analysis 
The quality control prior to statistical analysis of miRNA gain-of-function effects on target 
protein was performed by me using the RPPanalyzer package (v. 1.4.3) (von der Heyde, 
Sonntag et al. 2014). 
The remaining analyses described in this section were performed by the collaboration 
partner Astrid Wachter (Department of Medical Statistics led by Prof. Tim Beißbarth, 
University Medical Center Göttingen). 
All of the analyses described here were performed in the statistical environment R. 
  
2.2.6. Quality control 
Quality control of the RPPA incubation includes two steps: 
a) Dilution series control 
b) Target vs blank control 
The dilution series control plots the signal intensities of the four dilution curves against 
their concentration, for each separate target. In the same plot, it is also present the 
signal of the blank incubation performed with the same secondary Ab than the target-
specific incubation. The aim of the dilution series control is to examine whether the Ab 
incubated is able to detect the target in a linear manner over a concentration range that 
exceeds in both directions the one of all the lysates present in the screening. 
The target vs blank control plots the signal intensities of the target protein vs the ones of 
the corresponding blank for every sample present on the array. The aim is to detect if the 
signal is specific to the primary Ab used or if it derives from the secondary Ab incubation 
and is therefore experimental noise. 
 
Out of the initial 76 antibodies probed, 62 passed the quality control steps (see 2.1.11 in 
materials) 
 
2.2.7. miRNA-target interactions 
Signal intensities were normalized spot-wise with the Fast Green FCF method (Loebke, 
Sueltmann et al. 2007). Potential block effects dependent on the spotting of the lysates 
were removed by shifting the median value of each block to the overall median. At this 
step, microRNAs which had been transfected as part of the library were checked for their 
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current status in the miRBase repository (v21). Of the initial 810, 10 miRNAs were 
defined as dead entries of the database, having being recognized through time as 
fragments of other transcripts or due to the fact that they had previously only been 
computationally predicted. Another 6 miRNAs were merged with other entries, since they 
had been recognized as multiple entries of the same miRNA. Therefore the total amount 
of miRNAs tested downstream was 794.  
The package 'limma' (version 3.26.9) (Ritchie, Phipson et al. 2015) was used to identify 
differentially expressed proteins by comparing for each transfection round the signal 
intensities of the miRNA OE sample against the two mimic negative control values. 
Multiple testing correction was performed with the Benjamini-Hochberg method 
(Benjamini and Hochberg 1995). Visualization of moderated t-statistics (Ritchie, Phipson 
et al. 2015) was done using the package 'ComplexHeatmap' (version 1.6.0) (Gu, Eils et 
al. 2016), applying euclidean distance and the complete agglomeration method for 
unsupervised hierarchical clustering. 
 
2.2.8. Target prediction enrichment analysis 
Analysis concept by me and development by Astrid Wachter) 
TargetScanHuman (Agarwal, Bell et al. 2015) (v7) and MicroCosm Targets (Enright, 
John et al. 2003) (v5) databases were inspected to retrieve predicted miRNA-target 
relationships. TargetScanHuman database information was individually analyzed in 
regard to conserved and non-conserved miRNA binding sites. Fisher's exact test was 
used for enrichment testing, individually addressing downregulated miRNA-target pairs 
and upregulated miRNA-target pairs. Differential protein expression was considered 
significant below a false discovery rate (FDR) threshold of 0.1%. Only those miRNAs that 
had at least one significant interaction in the pathway of interest were considered for the 
testing. 
 
2.2.9. Network analyses 
The network analyses were performed at a visual level and at a mathematical level. 
a. Visual (analysis conceived and performed by Astrid Wachter) 
The visual analysis consisted in plotting only the most significant interactions (top 
100, by statistical significance) between miRNAs and target proteins of a single 
pathway. microRNAs with the highest amount of edges present in the graph could 
have been investigated further. Pathway graphs of interactions were generated with 
the package 'igraph' (version 1.0.1) by Astrid Wachter and then subsequently 
manually adjusted by me to render them visually helpful. 
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b. PC score calculations (analysis conceived together with Astrid Wachter and 
performed by her. Specifically the idea of permuting the FC matrix into a putative 
miRNA-pathway effect was mine, as well as the suggestion to test the scores against 
randomization) 
The mathematical analysis consisted into three steps. 
a) Identification of significant interactions. 
b) Permutation of the data matrix from miRNA-target into miRNA-pathway effect. 
c) Calculation of the total effect on pathway and statistical testing of the score. 
 
The results of the limma test consisted of two matrices: q-values (q-vals), which identify 
statistically significant interactions, and log2fold changes (log2FC), which identify to 
which extent the miRNA affects the protein. The interactions that had a q-value ≤0.001 
were considered significant (a). 
The log2FC were then permuted according to the known role of the target protein on the 
pathway. I assigned the role of the protein on the pathway based on the databases 
GeneCards® (http://www.genecards.org/) and KEGG pathway 
(http://www.genome.jp/kegg/pathway.html). 
Astrid Wachter then permuted the statistically significant FC according to the subsequent 
rule which aims to define the putative role of the miRNAs on the pathway as a whole: 
 
miRNA 
downregulates 
target − 
miRNA 
upregulates 
target + 
Protein is activator of pathway + −1 +1 
Protein is repressor of pathway 
− 
+1 −1 
 
The output is a data matrix where the +1 and -1 values are indicative of a putative effect 
of each miRNA on the pathway, based on the modulation of a specific protein. 
In this context, the extent of the FC is disregarded (b). 
 
The third step consisted in generating a score, termed pathway coregulatory (PC) score, 
which was calculated for each miRNA as the sum of all miRNA-mediated effects on the 
pathway, weighted by the number of measured proteins in the pathway. Permutation 
testing was performed to assess the miRNA-wise probability distribution of PC scores by 
10000x resampling the significant miRNA-protein interactions for each protein. PC 
scores were considered significant based on an alpha-level of 5%. (c) 
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The PC score calculation was the method of choice for proceeding with candidate 
microRNAs in downstream experiments. 
 
2.2.10.  WNT pathway stimulation and inhibition 
The WNT/β-catenin pathway was stimulated with mouse recombinant WNT3a 
(Peprotech) at a final concentration of 100 ng/ml, unless otherwise stated. WNT 
Signaling was inhibited by treating cells with iCRT14 (Santa Cruz, CA, USA) at a final 
concentration of 10uM, unless otherwise stated. Control treatments were 0.1%BSA in 
PBS and DMSO, respectively. 
 
2.2.11.  Cell proliferation assay 
231 cells were plated at a density of 5x104 in 96-well, black plates with transparent 
bottom (Greiner). The subsequent day cells were transfected as in 2.2.2.3 or treated with 
the WNT-pathway inhibitor iCRT14. Cell nuclei were stained with Hoechst 33342 
(Thermo Scientific) at a final concentration of 20 uM at 48, 72, and 96 hours post-
transfection/post-treatment and imaged using an Olympus microscope with 4x objective 
(Olympus). Quantification of Hoechst+ nuclei was performed with in-built software. 6 
technical replicates were performed for each experiment. Median for the 6 tech 
replicates was used for calculating the ratio of the treatment over the control. The data 
was loaded into GraphPad Prism 5 software and the ratios of 4 different biological 
replicates were used for statistical testing (Student’s t-test, two tail). 
 
2.2.12.  FACS analysis of CD24 and CD44 surface markers expression 
231 cells were plated at 2.5x105 per well and then transfected with the same protocol as 
in 2.2.2.2. In alternative, cells were treated with iCRT14. Throughout the protocol, cells 
were always detached from plastic surfaces using a non-enzymatic dissociation buffer to 
prevent damaging the surface markers. Centrifugations were all performed at 4ºC and 
cells were kept on ice throughout the whole procedure to minimize cell death. 
2 days post-transfection/-treatment, cells were split 1:2. 4 days post-transfection/-
treatment, cells were detached, counted, and washed 1x with the Assay Buffer (2%FBS 
in PBS cold). Then 100’000 cells per condition were plated in a deep-well plate where 
they were resuspended in 100 ul of Assay Buffer containing the appropriate antibody 
mix. 
 ng/well ul vol 1x 
Anti-CD24 APC-conj Biolegend 25 0.25 
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Isotype G2k APC-conj 25 0.25 
Anti-CD44 PE-conj 120 0.6 
Isotype PE-conj 120 0.6 
Assay buffer  100 ul 
 
Samples were stained for 45’ on ice, protected from light. After 2x washing in Assay 
Buffer, cells were transferred to a FACS tube through a filtering cap and measured at 
FACS Canto II with the voltage settings listed. 
 
Detection 
channel 
Voltage 
Forward Scatter 181 
Side Scatter 410 
PE 342 
APC 460 
 
6 separate biological replicates were performed, with 2 technical replicates each. 
Analysis of cell population percentages was performed on FACS Diva software, with 
gating based on the isotype controls for each specific sample. 
The data was loaded into GraphPad Prism 5 software tested with a two-tailed Student’t t-
test to compare percentages of treated vs. control-treated samples. 
 
2.2.13.  Mammosphere formation in ultra-low attachment conditions 
231 cells were plated at 2x105 per well and transfected the next day with the same 
protocol as in 2.2.2.3. In alternative, cells were treated with iCRT14. Two days after 
transfection, cells were detached, counted, re-suspended in mammosphere medium 
(see 2.1.9) and plated in ultra-low attachment 6-well plates at a final density of 530 
cells/cm2. For cells treated with iCRT14, the treatment was continued also during the 
mammosphere formation. 7 days after transfer, 1 ml of fresh mammosphere medium 
was added to each well. 14 days after transfer, cells were stained for 30’ with Calcein 
AM (final conc. 1uM). 
Imaging was performed on a Zeiss Cell Observer equipped with EC Plan-Neofluar 
2.5x/0.075 objective. 
The subsequent parameters were used for the image acquisition: 
- Excitation source: LED Colibrí LED at 470 nm at 100% of power 
- Filter block: 38 HE GFP 
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- Detector: gray scale CCD camera AxioCam. 
- 90 msec exposition 
- Tile function: 90% coverage of well with 5% tiles overlap 
 
Images where exported as tiff files and processed using the Fiji software, using the 
analyze particle function. Particles bigger than 50 µm in diameter were counted as 
spheres. 
 
Due to the possible subjectivity in the analysis of images deriving from the 
mammosphere formation assay, the experiment was performed blinded. A member of 
the division would re-label the tubes prior to plating the cells in ultra-low attachment 
conditions. After imaging and quantification, I was given the key to resolve the sample 
origin. 
The percentage of sphere-forming cells was calculated for every well as (number of 
spheres/number of cells)*100. 
 
2.2.14. Invadopodia formation on fluorescent gelatine 
a. Fluorescent gelatin coating of glass coverslips 
Glass round coverslips are pre-coated with Poly-L-lysine (final conc. 0.1 mg/ml in PBS) 
for 20’ at RT. After 1x wash with PBS, they were primed with 1 ml glutaraldehyde 0.5% in 
PBS for 15’ at RT. After 3x washes with PBS, coverslips were coated with a fluorescent 
gelatin mix (Oregon Green® 488 Conjugated Gelatin diluted in clear gelatin 1:8) for 15’ 
protected from light. After 3x washes with PBS, the glutaraldehyde was reduced by a 
short and sharply timed 3’ incubation with sodium borohydrate freshly prepared at 
5mg/ml. The coverslips were then washed 6 to 8 times with PBS to get rid completely of 
the sodium borohydrate. Coverslips were stored at most 1 week at 4ºC prior to use. 
 
b. Invadopodia formation assay 
231 cells were plated at 2x105 per well and transfected the next day with the same 
protocol as in 2.2.2.2. Two days later, 50’000 cells were transferred in a well of a 12-well 
plate containing a gelatin-coated coverslip. 10 hrs post-transfer, cells were fixed in 4% 
PFA, permeabilized in 0.3% Triton X-100, and subsequently blocked in 3% BSA in PBS. 
Coverslips were then incubated O.N. at 4ºC with Ab anti-TKS5 (1:300 in 1% BSA-PBS). 
The next day, they were washed 3x in 1% BSA-PBS, and then stained with DAPI (1 
ng/ml), Rhodamin phalloidin (1:400), and a goat anti-rabbit Alexa 633 conjugated 
secondary Ab (1:400) for 1h 30’ at RT. After 3x washes in PBS and 1x in milliQ water, 
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the coverslips were mounted on glass slides with the ProLong Gold medium and allowed 
to dry overnight prior to imaging. 
 
Coverslips were inspected on a confocal Zeiss LSM 780 microscope equipped with a 
Plan-Apochromat 63x/1.40 Oil Ph3 M27 objective.  
The detection of different fluorophores was performed with the subsequent wavelengths. 
 
Structure fluorophore/stain excitation emission laser 
Nuclei DAPI 405 415-478 UV diode 
Gelatin Oregon Gr 488 488 498-550 Argon Multiline 
Actin Rhodamin 561 571-620 DPSS 
TKS5 Alexa 633 secondary Ab 633 643-660 HeNe 2 
 
For each coverslip, at least 60 cells were counted and defined as positive for 
invadopodia formation if they presented actin foci concomitant with TKS5 staining and 
clear holes in the fluorescent gelatin layer. Representative images of invadopodia+ cells 
were acquired as z-stacks of 18 images for a total of 5.5 um. 
 
The experiment was performed in 3 biological replicates, with 2 coverslips quantified for 
each experimental condition in each replicate. Due to the possible subjectivity in the 
quantification of cells from the fields, the experiment was performed blinded. A member 
of the division would re-label the tubes prior to transfection. After imaging and 
quantification, I was given the key to resolve the sample origin. 
 
Percentages of positive and negative cells were plotted as mean and standard error of 
the mean (statistics: Student’s t-test, two-tailed). 
 
2.2.15.  3’ UTR cloning 
To prove direct interactions between microRNAs and target mRNAs, 3’UTR cloning 
downstream a luciferase reporter gene is a necessary step. The section describes all the 
steps taken to produce the plasmids used for the downstream luciferase assays (2.2.11). 
 
a. Target prediction 
The TargetScan (v 7.1) database was used as the main platform for target prediction. A 
total of 23 putative binding sites for miR-193b, miR-409, and miR-494, were identified on 
the 3’UTRs of 9 target genes. TargetScan also describes the most prevalent transcript 
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isoform, according to 3P-seq tags. The sequence of the suggested 3’UTR was 
downloaded by the ENSEMBL database and uploaded in the Benchling online tool to 
proceed with primer design. For APC and CTNNB1, some nucleotides of the ORF were 
included in the sequence since the first predicted binding site was too close to the end of 
the ORF to design optimal cloning primers. 
 
b. Primer design 
Primers were manually designed to span as many binding sites as possible, however it 
wasn’t possible for all the genes to clone full UTRs and some were divided into smaller 
portions (termed cloning area 1, 2, etc) 
A total of 15 fragments corresponding to the 9 UTRs were cloned. 
Primers were designed to have a GC content between 35 and 55%, Tm 50ºC to 60ºC 
(matched FWD and REV with max 1ºC difference between each other), and a maximum 
of 2 kB of fragment. FWD and REV primers were designed to have XhoI and NotI 
restriction sites respectively for end-cloning into PsiCheck2 vector. 
All primers are listed in section 2.1.13. 
 
c. PCR to amplify fragments 
cDNA from MDA-MB-231 was generated with the Reverd Aid H Minus M-MulV RT kit, 
using oligo-dT as RT primers 
 PCR reaction mix x1 
5x Phusion HF Buffer 10 
10 mM dNTPs  1 
primer A (10uM) 2 
primer B (10uM) 2 
template cDNA  
(~200ng) 
1.3 
Phusion Hot Start 0.5 
H2O  32.7 
50 mM MgCl 0.5 
total vol 50 
 
PCR thermic profile 
Step temperature time cycles 
Initial denaturation  98°C  5’   
Denaturation 98°C 10” 35 cycles 
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Annealing  Optimized 30” 
Extension 72°C 2’ 
Final Extension 72°C 10’   
Annealing temperature was optimized for fragments amplified with primers that had 
similar Tm. The temperatures were ranging between 46ºC and 57ºC. CSNK1A1 
amplification required a 2-step PCR where annealing was skipped and the profile 
proceeded directly to extension, due to the high Tm of the primers. 
 
d. Cloning into pCR®2.1 vector to screen for fragment sequences 
PCR products were run on a 2% Agarose gel and fragment of the correct size were 
excised and purified with the Wizard SV Gel and PCR Clean-up kit. After addition of an 
adenosine to each end of the purified products, the fragments were cloned into pCR®2.1 
vector by an O.N. ligation at 18ºC. The subsequent day DH5α bacteria were transformed 
with the ligated vector and plated onto XGal coated LB-Agar+Amp plates. 
This technique allows to quickly identify clones which had an integration event, since the 
self-ligated vector is able to process the XGal and therefore colonies are blue. 
The next days, colonies which were white were picked, growth in 5 ml of LB+Amp broth, 
purified with QIAprep Spin Miniprep kit, and send for sequencing wit M13 FWD and M13 
REV primers. 
 
Plasmid that presented the correct sequence were digested O.N. at 37ºC with XhoI and 
NotI enzymes. 
Digestion reaction x1 
NEB3 buffer 3 
Xho I 1 
Not I 1 
BSA 100x 0.3 
template (mini) 3 ug 24.5 
 
The subsequent day, the digestion products were run on a 2% Agarose gel and bands of 
the correct size were excised and purifies as above stated. 
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e. Cloning into psiCheck2 
The fragments were then subcloned into a psiCheck2 vector predigested with XhoI and 
NotI, as well as treated with Antarctic Phosphatase to help preventing self-ligation of the 
backbone. In the ligation reaction, PmeI restriction enzyme is added to reduce the 
chance of empty vectors since it would cut in the multiple cloning site of psiCheck2 in 
case it had previously been digested only with one of the two proper restriction enzymes. 
 
Ligation reaction x1 
PmeI 1 
Template (UTR) to 6.6 fragment + H2O 
10X Ligation Buffer  1 
psiCHECK_Xho-Not 0.46 (=50ng) 
T4 DNA Ligase 1 
Final volume  10 
 
Ligation proceeded O.N. at 18ºC. 
The subsequent day DH5α bacteria were transformed with the ligated vector and plated 
onto LB-Agar+Amp plates. The next days, colonies were picked, growth in 5 ml of 
LB+Amp and the plasmids were purified with QIAprep Spin Miniprep kit. After 
sequencing to confirm the correct insertion, bacterial clones were cultured in 50ml of 
LB+Amp broth and plasmids were purified with NucleoBond Xtra plasmid purification kit 
(Machery-Nagel). 
 
f. Mutagenesis of miRNA binding sites 
To prove that the miRNA affects the luciferase with a direct interaction with the 3’UTR it 
is necessary to perform rescue experiments by mutating the putative miRNA binding 
sites. Here, we aimed at mutating the 3 nucleotides of the 3’UTR which match the nt 3-5 
of the miRNA seed. 
Mutagenesis primers (listed in 2.1.13) were manually designed to anneal with perfect 
Watson-Crick base pairing at least 20 nt upstream and downstream the 3 nt to mutate. 
Mutagenesis PCR was performed with the QuikChange Lightning Site-Directed 
Mutagenesis Kit. 
Mutagenesis PCR mix x1 
dsDNA WT 100 ng 
FWD mutagenesis primer 125 ng 
REV mutagenesis primer 125 ng 
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dNTP mix 1 
QuikSolution reagent 1.5 
10x reaction buffer 5 
QuikChange Lightning 
enzyme 
1 
NF-free H20 to 50 
 
PCR thermic profile 
Step temperature time cycles 
Initial denaturation  95°C  2’   
Denaturation 95°C 20” 
18 cycles Annealing  60°C 10” 
Extension 68°C 4’ 30” 
Final Extension 68°C 5’   
 
For 3’UTRs containing multiple predicted binding sites, the mutagenesis of all was 
performed with the QuikChangeLightning MultiSite kit. 
 
  x1 
10× QuikChange Lightning Multi reaction buffer 2.5 
QuikSolution (DMSO) 0.75 
ds-DNA template (prediluted to 100 ng/ul) 100 ng 
primers for each binding site 100 ng/each 
dNTP mix 1 
QuikChange Lightning Multi enzyme blend 1 
NF-h20 to 25 
 
PCR thermic profile 
Step temperature time cycles 
Initial denaturation  95°C  2’   
Denaturation 95°C 20” 
30 cycles Annealing  55°C 10” 
Extension 65°C 5’ 
Final Extension 65°C 5’   
 
Dissertation  Chiara Giacomelli 
 
 
 
63 
Immediately following each of the mutagenesis PCR, 2 ul of DntpI enzyme were added 
to each reaction and incubated at 37ºC for 5'. DH5α bacteria were then transformed with 
the PCR products and growth on LB-Agar+Amp plates. Colonies were picked and grown 
in 5 ml LB+Amp broth. Plasmids were harvested with QIAprep Spin Miniprep kit. After 
sequencing to confirm the correct mutations, bacterial clones were cultured in 50ml of 
LB+Amp broth and plasmids were purified with NucleoBond Xtra plasmid purification kit 
(Machery-Nagel). 
Prior to using the plasmid in luciferase reporter assay, they were all sent for sequencing 
with psiCheck2 specific primers to confirm that the cloned portions represented the 
correct sequence, as well as the desired mutations. 
 
2.2.16. Luciferase reporter assay 
Reporter assays were exploited throughout the project to test two different hypotheses. 
a) 231 cells with stably integrated firefly luciferase under the control of 6 responsive 
elements for β-catenin (see 2.2.1) were used to test whether miRNA O.E. affected 
responsiveness to WNT stimulation. 
b) 3’UTR reporter assays were instead performed to test whether there is a direct 
interaction between the miRNA of interest and the target genes. For this second type 
of assay, the activity of both firefly and renilla luciferase were assessed in order to 
normalize for transfection efficiency. 
For an overview of the timeline of experiments, see end of the chapter 
 
Cells plated in white bottom 96-well plates and transfected/treated/stimulated were 
washed 1x with PBS and then lysed into 50 ul of M-PER buffer supplemented with DTT 
(final conc 2 mM). After 10’ of lysis, the plates were read on a TECAN plate reader 
equipped with injectors primed with luciferase mixes. In the 3’UTR reporter assays, the 
lysates were supplemented with 50 ul of PBS, then divided into two different plates in 
order to read both firefly and renilla activities. 
 
For β-catenin reporter experiments, firefly signal intensities were averaged through 6 
technical replicates, and then a ratio between the miRNA transfection and the control 
transfection was calculated. Data representation and statistical testing were performed 
on GraphPad Prism 5 software. Ratios from 4 biological replicates were used for 
statistical testing (two-tailed, Student’s t-test). 
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For 3’UTR reporter experiments, the data was first normalized for transfection efficiency 
by dividing renilla over firefly signal intensity. Ratios were then averaged through 4 
technical replicates. Data was then normalized over an empty vector control to normalize 
for miRNA effects on the plasmid backbone. Eventually, a ratio between the miRNA 
transfection and the control transfections was calculated. Data representation and 
statistical testing were performed on GraphPad Prism 5 software. Ratios from 3 
biological replicates were used for statistical testing (two-tailed, Student’s t-test). 
 
 
Firefly 
substrate/well 
Fin Conc.(mM) 
Stock 
Conc.(mM) 
x1 
Tricine 40 500 4 
ATP 2 100 1 
MgSO4 10 100 5 
EDTA 0.5 500 0.05 
DTT 10 1000 0.5 
CoA 1 20 2.5 
Luciferin 1 25 2 
ddH2O - - 34.95 
 
Renilla 
Substrate/well 
Fin Conc.(mM) 
Stock 
Conc.(mM) 
x1 
Coelenterazine 0.05 2 1.25 
EDTA 8 500 0.8 
DTT 10 1000 0.5 
ddH2O - - 47.45 
 
2.2.17. Gene and miRNA expression analyses 
1. RNA extraction 
Cells cultured in 6-well plates and transfected were lysed in 700 ul of QIAzol reagent. 
Total RNA extraction was then performed using the miRNeasy mini kit. 
Samples belonging to WNT stimulation and inhibition experiments were additionally 
digested on column with DNaseI to deplete the residual genomic DNA from the 
preparation. 
 
2. miRNA quantification 
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RT was performed using TaqMan® MicroRNA Reverse Transcription Kit. 
miRNA-RT mix x1 
Nuclease Free Water 1.664 
10x RT Buffer 0.6 
100mM dNTPs 0.06 
RNAse Inhibitor 0.076 
Multiscribe 0.4 
Total pre-mixed with gene specific 
primer 
2.8 
5x Primer 1.2 
Total gene-specific 4 
 
Thermic profile 
Time Temp. 
30’ 16°C 
30’ 42°C 
5’ 85°C 
∞ 4°C 
 
RT product was diluted 1:5 in NF-H2O. Quantitative PCR was performed with TaqMan® 
Universal PCR Master Mix, no AmpErase™ UNG. Assays listed in 2.1.13. 
Component x1 
20x primers mix 0.45 
Universal PCR Master 
Mix 
3.6 
Nuclease Free Water 0.95 
total 5 
 
Thermic profile  
Time Temp  
2' 50°C 
 
15' 95°C 
 
15'' 95°C x 45 
cycles 60'' 60°C 
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3. mRNA 
RT was performed using with ReverdAid H Minus First Strand cDNA Synthesis Kit. 
An oligo(dT) annealing mix was added to 2 ul of diluted RNA (100ng to 5 ug) 
oligo(dT) annealing x1 
oligo(dT) primers (100 pmol/µl) 1 
RNase-free water 9 
Total 10 
Then incubated 5’ at 70ºC, then cool on ice. Master mix was then added. 
RT master mix x1 
5x reaction buffer 4 
RiboLock Ribonucl Inhibitor (20u/µl) 1 
10mM dNTP mix 2 
Reverd Aid H Minus M-MulV RT 
(200u/µl) 
1 
Total 8 
 
Thermic profile 
Time Temp. 
5’ 37°C 
60’ 42°C 
10’ 70°C 
∞ 4°C 
 
RT product was diluted in NF-H2O and qPCR was performed with the 2x SsoAdvanced™ 
Universal SYBR® Green Supermix. 
SYBR Master Mix x1 
SsoAdvanced™ Universal SYBR® 
Green (2x) 
5 
FWD primer (250nM final) 0.25 
REV primer (250nM final) 0.25 
cDNA 2 
NF-H20 2.5 
final 10 
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Thermic Profile 
 
95°C 30" 
 
95°C 10'' 
x 45 cycles 
60°C 1' 
melting curve analysis 
 
 
Data was analyzed with manual thresholding and ΔRn on SDS 2.2.2 software. Ct values 
were analyzed with the ΔΔCt method. 
 
2.2.18. Western Blot 
Two days after transfection (as 2.2.2.2), cells were pelleted using trypsin. Cell pellets 
were lysed in M-PER buffer (Perbio Science) and after 30’ rotation in cold room, the 
lysates were cleared at 13’000 rpm, 15’, 4ºC. Protein concentration was assayed with 
BCA kit. Prior to gel loading, samples were mixed with 6x Rotiload and boiled for 5’ at 
95C. 15 ug of protein were loaded per lane on 4–20% Mini-PROTEAN® TGX™ 
precasted gel and run 1h 30’ at 120V. Proteins were then transferred onto a PVDF 
membrane using a semi-dry cassette for 1h at 25V. Membranes were blocked in 1:1 
Rockland-TBS for 1h at RT, and then incubated overnight with primary Ab specific for the 
protein of interest. After washings in TBS-T, membranes were incubated for 1h at RT in 
light-protected condition with secondary Ab conjugated with 600 or 700 nm emitting 
fluorophores diluted in TBS-T. After washings in TBS-T, membranes were imaged using 
an Odyssey scanner. The same membranes were then incubated overnight in 
Rockland:TBS with primary antibody for normalizers. After washing and incubation with 
secondary antibody emitting in the different channel, membranes were imaged to 
normalize for uniform loading. Signal intensity from the band was extracted with the 
imageStudio software. Ratio over the normalizer data was performed to correct for gel 
loading. 
Primary and secondary Ab were used with the dilutions listed in 2.1.11. 
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Timepoints of experiments 
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3. Results 
Dissecting the miRNome impact on metastatic pathways in triple negative 
breast cancer 
3.1. High throughput targeted proteomics 
The workflow of the proteomic screening is outlined in figure 3.1. The first step 
corresponds to the generation of protein lysates of MDA-MB-231 cells transfected 
with a library of 800 miRNAs. This material was prepared by Stefan Uhlmann, a 
previous PhD student of the division of Molecular Genome Analysis (Uhlmann, 
Mannsperger et al. 2012). The samples had been optimized for assaying miRNA 
gain of function effects with reduced off-targets effects. Dr. Uhlmann had 
transfected cells with a range of mimic concentrations (1 to 100 nM) and 
evaluated via Western Blot the knock-down of proteins for miRNA-target 
interactions already validated in literature. He determined that 25 nM was 
delivering the best cost-benefit performance. Indeed, at higher concentrations (50 
and 100 nM) only a marginal additive effect was detectable, accompanied by a 
higher chance of off-target effects. 
 
Figure 3.1 Workflow of the miRNome screen 
 
At the beginning of my project, the three pathways to investigate (c-Met, integrin 
signalling, and WNT/β-catenin) were defined. RNA-sequencing data of MDA-MB-
231 available in house was exploited to define whether the mRNAs 
corresponding to targets belonging to the three pathways of interest were 
expressed. Antibody validation was performed on a panel of cell lines as 
described (Golan-Lavi, Giacomelli et al. 2017). This antibody validation protocol 
characterizes the specificity of antibodies via Western Blot not only in the cell line 
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of interest, but in additional ones as well, increasing the confidence in RPPA 
signal. The antibodies of interest which passed the WB validation were probed on 
arrays spotted on nitrocellulose coated slides (RPPA). After data quality control, 
our collaborators Astrid Wachter and Tim Beißbarth (Department of Medical 
Statistics, Universitätsmedizin Göttingen) quantified the effects of single miRNAs 
on target protein expression (q-values and log2 fold changes). The data was then 
exploited to define a network of interaction which would be pathway-specific. To 
do so, we developed in collaboration with Astrid and Tim a score that summarize 
the effects taking into consideration the protein role on the networks (network 
analysis). 
 
3.2. Identification of targets of interest 
The targets belonging to the three pathways were defined based on the KEGG 
pathway database repository (Kanehisa, Sato et al. 2016). WNT/β cat canonical 
pathway (map04310) as well as focal adhesion signalling (map04510) were 
queried as provided, while for c-Met, the network was built based on map04151 
and map05200, corresponding to PI3K-Akt signalling and pathways affected in 
cancer networks, respectively (Kanehisa, Sato et al. 2016). 
Considering different isoforms for receptors or kinases present in the pathways, 
the total amount of target selected was 155. Of those, 34 were not expressed in 
the cell line of interest. Therefore, 121 candidate target proteins remained listed. 
Antibodies to probe the corresponding target were searched. However, few 
targets proved very challenging and were therefore discarded a priori: 
- Membrane proteins for which antibodies were available uniquely for the 
extracellular portion. This was an experimental constraint deriving from the 
fact that the cell had been trypsinized prior to protein isolation. As a 
consequence, the experimental procedure might have affected potential 
signal reduction quantified via antibody-detection. 
- Proteins with multiple isoforms. In particular WNT ligands and Frizzled 
receptors, Integrins and myosin light chain kinases. For many of these 
targets, antibodies were not available for isoform-specific detection. 
Therefore, rather than risking a highly complex deconvolution analysis 
downstream, the targets were not probed. 
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The total amount of targets for which antibodies were searched and tested were 
95. Of those, 76 passed quality criteria in WB analysis and were therefore probed 
in the HTS to quantify of miRNA-mediated effects on proteins. Of these, 62 
passed the quality control of the RPPA pipeline and the data gathered from their 
incubation was used for downstream analyses. 
 
3.3. miRNA regulate only mildly their targets 
The effect of the miRNome on the expression of all our targets of interest was 
quantified with the limma method by Astrid Wachter. Every miRNA OE sample 
was tested against the 4 microRNA mimic negative controls that were transfected 
in the same round of cell culture (performed by Stefan Uhlmann). Subsequent to 
the limma test, the Benjamini-Hochberg method was used to correct for multiple 
testing.  For the analysis, we intentionally discarded the z-score method, used in 
the previous miRNome screen (Uhlmann, Mannsperger et al. 2012). This choice 
was based on the fact that within sample groups, a variable amount of miRNAs 
belonging to the same family (i.e. putatively targeting a similar subset of targets). 
Since the z-score exploits the average and standard deviation of the whole group 
of samples to define the miRNA-dependent effect, the presence of miRNAs 
putatively affecting similar subgroups could create a bias that could potentially 
hinder significant interactions. Therefore, the limma test was preferred in order to 
control this form of bias. 
  
The final output of the analysis corresponded to fold changes in log2 scale as 
well as q-values to describe the statistical significance of the variation of target 
protein expression compared to the mimic negative controls. 
miRNA-target interactions are represented by means of heatmaps of the 
moderated t-statistics, a visualization suggested by Astrid Wachter as a form that 
combines both pieces of information (log2FC and q-value). Unsupervised 
hierarchical clustering was performed on the miRNA-mediated effects, applying 
euclidean distance and the complete agglomeration method. 
The results are shown in figure 3.2 A for WNT/β-catenin pathway and in 
supplementary figures 1 and 2 for the other two pathways. 
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As it can be noted from the heatmaps representing the t-statistics, within each 
pathway there seems to be many miRNAs affecting the expression of multiple 
targets probed. Therefore, to ensure that the interactions exploited in 
downstream analysis are specific, only interactions which pass a very stringent 
statistical significance cutoff (q-value ≤ 0.001) were taken into account for all the 
downstream analyses. 
 
The average of negative significant log2 fold changes throughout the HTS is -
0.52 (fig. 3.2 B), corresponding to roughly a 30% reduction in expression, 
consistent with the known mild effect that miRNAs generally induce on the 
majority of the targets (Baek, Villen et al. 2008, Selbach, Schwanhausser et al. 
2008). 
 
Target-wise analysis of the distribution of the log2 FC as well as the q-values by 
means of volcano plots shows that few targets have a small number of miRNAs 
which induce very strong effects. However, for the majority of the cases, 
statistically significant interactions are relatively little in fold change. This is the 
case for APC (fig. 3.2.C), for which we have significant repression of a target 
already at -0.17 log2FC (roughly 10% reduction in expression). On the other 
hand, β-catenin fold changes pass the significance threshold much later, with 
values of – 0.27 and +0.54. In contrast with APC, this is associated with overall 
stronger repression and overexpression dynamics which range between -1.4 and 
+ 0.9. Volcano plots for all the targets analysed are available in supplementary 
figure 3. 
This mild effect on multiple target proteins prompted us to analyse the pathways 
with a system biology approach. The hypothesis is whether by analysing many 
mild, but highly significant interactions induced by a single miRNA we are able to 
identify powerful modulators of the whole pathway. 
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Fig 3.2 Effect of the miRNome on target proteins. A The heatmap represents the 
moderated t-statistics for the miRNA-target interactions for the WNT/β-catenin pathway. 
Proteins are given as column and miRNAs as rows. Downregulations of targets is in 
green, while upregulation is represented in purple. The miRNA effects are clustered 
applying euclidean distance and the complete agglomeration method. Clustering tree is 
given in supplementary figure. For clarity, names of the target proteins are listed with the 
corresponding target gene name. In supplementary table 1 the corresponding protein 
names are listed. B The average negative effect of miRNAs on the targets through the 
whole screen is represented in a box plot. Whiskers represent the 10th and 90th 
percentile. Dotted line marks the average negative log2 FC. C The two volcano plots 
represent the distribution of miRNA-mediated effects on APC (top) and β-catenin 
(bottom). The x-axis represents the log2FC and the y-axis represents the q-value in 
log10 scale. The horizontal red line represents the q-value cutoff. The vertical lines show 
for each protein the minimum log2FC value that passes the q-vals cutoff, both for 
downregulations and upregulations. 
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3.4. The downregulation of target proteins is mostly mediated by predicted 
interactions in the 3’UTR of the corresponding mRNA  
The predominant way a microRNA affects target mRNAs and protein levels, is via 
base pairing its ‘seed sequence’ (nt 2-7) with one or multiple MBSs positioned in 
the targets’ 3’UTRs. 
Therefore, in collaboration with Astrid, the results of the miRNome screen were 
tested for enrichment of significant interactions within MBS prediction databases. 
Two different databases were analysed: TargetScan (v7) and MicroCosm Targets 
(v5). Significant upregulations and significant downregulations were 
independently tested, with the former serving as an internal negative control. 
Indeed, upregulations induced by miRNA OE are expected not to be dependent 
on 3’UTR predicted MBSs. TargetScan (TS) additionally provides information on 
the conservation of the MBS. Thus, in our enrichment analysis, we kept distinct 
the MBS conserved among mammals and the non-conserved ones. Fisher’s 
exact test was used to calculate the enrichments, recapitulated in table 3.1.  
 
Table 3.1 List of targets analysed with corresponding p-value for enrichment of 
predicted miRNA binding sites. In yellow are highlighted the enrichments which 
pass the significance threshold of p-value ≤ 0.05 
Gene 
name 
Significant 
downregulations tested 
Significant upregulations 
tested 
 
TS 
Cons 
TS 
NC 
MCT 
TS 
Cons 
TS 
NC 
MCT 
AKT1 0.000 0.005 1.000 1.000 0.280 1.000 
AKT2 0.131 0.884 0.060 1.000 1.000 1.000 
APC 0.004 0.009 0.434 0.236 0.465 1.000 
BRAF 1.000 0.668 1.000 1.000 1.000 1.000 
CCND1 0.000 0.000 1.000 1.000 0.006 1.000 
CCND3 0.002 0.000 0.169 1.000 0.045 0.389 
CDH1 1.000 0.320 1.000 0.094 0.270 0.375 
CDK2 0.000 0.032 0.004 1.000 1.000 1.000 
CDK4 0.347 0.461 0.548 1.000 1.000 1.000 
CDKN1B 0.000 0.006 0.370 0.202 0.033 0.350 
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CRK 0.045 0.526 0.524 0.006 0.300 1.000 
CSNK1A1 0.013 0.018 1.000 1.000 0.747 1.000 
CSNK1E NA 1.000 0.142 NA 1.000 0.615 
CSNK2A1 1.000 0.356 0.257 1.000 0.570 1.000 
CSNK2B 1.000 0.079 0.565 1.000 0.600 1.000 
CTNNB1 1.000 0.013 0.703 1.000 0.129 0.460 
CTNNBIP1 1.000 1.000 1.000 1.000 1.000 0.352 
DIAPH1 0.522 0.732 0.275 1.000 0.438 0.615 
DUSP6 0.031 0.101 0.410 1.000 1.000 1.000 
DVL3 0.516 0.205 0.373 0.184 1.000 0.354 
EGFR 0.000 0.000 0.555 1.000 1.000 1.000 
FOS 1.000 0.446 1.000 1.000 0.518 0.687 
GRB2 0.000 0.000 0.124 1.000 0.717 1.000 
GSK3B 0.003 0.001 0.133 1.000 1.000 1.000 
HRAS 1.000 1.000 0.344 1.000 0.411 0.531 
ILK 0.078 0.548 0.856 1.000 1.000 1.000 
JUN 1.000 0.381 0.062 1.000 0.144 1.000 
LRP5 1.000 0.641 0.730 1.000 1.000 0.236 
LRP6 0.656 0.088 0.782 0.111 0.110 0.814 
MAP2K1 0.001 0.166 0.521 1.000 0.711 1.000 
MAPK1 0.434 1.000 1.000 1.000 0.233 1.000 
MAPK14 0.019 0.000 1.000 0.026 0.026 1.000 
MAPK3 0.212 0.015 0.711 1.000 0.713 0.569 
MAPK8 0.000 0.447 1.000 0.040 1.000 0.525 
MET 0.000 0.000 0.232 1.000 0.197 0.399 
MTOR 0.003 0.002 1.000 1.000 0.416 1.000 
PAK1 1.000 0.333 0.374 1.000 0.225 1.000 
PAK2 1.000 1.000 1.000 0.411 0.463 1.000 
PDPK1 0.315 1.000 0.123 1.000 0.426 1.000 
PIK3CA 0.003 0.135 0.017 0.185 0.491 1.000 
PIK3CB 0.005 0.163 0.253 0.377 0.465 0.597 
PLCG1 0.000 0.011 0.010 1.000 0.173 1.000 
PPP1CA 1.000 0.101 1.000 1.000 1.000 1.000 
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PRKCA 0.309 0.085 1.000 1.000 0.249 1.000 
PSEN1 0.072 0.178 0.305 0.437 0.325 1.000 
PTEN 0.000 0.019 1.000 0.245 0.457 1.000 
PTK2 0.020 0.233 0.501 1.000 1.000 0.615 
PTPN11 0.001 0.416 1.000 1.000 1.000 1.000 
PXN 0.105 0.027 0.397 1.000 0.404 1.000 
RAC 1.000 1.000 1.000 1.000 1.000 1.000 
RAP1A 0.001 0.014 0.639 0.368 1.000 1.000 
RB1 0.064 0.053 0.484 1.000 0.060 0.222 
RHOA 0.223 1.000 0.367 1.000 0.132 1.000 
ROCK1 0.000 0.593 0.069 1.000 0.260 0.182 
ROCK2 0.003 0.000 0.153 1.000 0.412 1.000 
SENP2 0.134 1.000 0.295 1.000 0.542 1.000 
SHC1 0.013 0.307 1.000 1.000 0.137 0.364 
SOS1 0.073 0.701 1.000 0.197 0.716 0.658 
SRC 0.035 0.829 1.000 1.000 0.548 1.000 
STAT3 0.105 0.006 0.012 0.323 0.507 1.000 
TP53 0.053 0.382 1.000 0.288 1.000 1.000 
 
Results show that roughly 45% of the targets probed have a significant p-value 
when tested for enrichment of predicted conserved binding sites (TS Cons). The 
percentage drops to 34% for the nonconserved predicted sites (TS NC). The 
MicroCosm Targets (MCT) returns only a 6.5% of targets with significant 
enrichment, possibly due to prediction algorithm which is less restrictive than the 
TargetScan one. For the upregulations, we also identify roughly 6% of targets 
which have a significant enrichment. This can be explained by the fact that the 
predictions are often redundant (i.e. false positive) or might be non-functional in 
specific cellular contexts. 
 
A hypothesis formulated on the basis of the results of the screening performed by 
Stefan Uhlmann, was that the length of mRNAs’ 3’UTRs could correlate with the 
amount of repressions identified. On the contrary, upregulations, being not 
dependent on 3’UTRs, should not correlate. Therefore, 3’UTRs sequences of the 
genes investigate in this screening were analysed to compare their length with 
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the amount of significant positive or negative interactions. As well, the length of 
3’UTRs was compared to already validated miRNA:target interactions 
(miRTarBase MTI database) (Chou, Chang et al. 2016). All the data is available 
in supplementary table 1 found on CD due to size limitations. 
 
For specific genes a trend seemed to be there, such as CDKN1B (1774 nt.) 
which shows a clear tendency to upregulation with 224 miRNAs, while only 28 
downregulate its expression. However, correlation analysis between 3’UTR 
length and the amount of significant downregulation did not return a significant p-
value. Pearson’s r was -0.026 (fig. 3.3). The hypothesis that mRNAs with longer 
3’UTRs would be under a stronger regulation by microRNAs was therefore 
refuted. 
 
Figure 3.3. 3’ UTR length does not significantly correlate with downregulations 
detected at the protein level. 3’UTRs lengths (x-axis) are plotted against the amount of 
significant downregulations (y-axis, left plot) or against the significant upregulations (y-
axis, right plot) detected at the protein level. 
 
In summary, in collaboration with Astrid Wachter, the high throughput targeted 
proteomic approach successfully described the effects of 800 microRNAs on 62 
proteins belonging to c-Met, Integrin, and WNT/beta-catenin signalling pathways. 
Additionally, more than 50% of the downregulations identified were found 
enriched for predictions of miRNA binding sites in the 3’UTRs of the target 
mRNAs. The mild effects detected at the protein level and the target prediction 
enrichment results were in line with previously known biological mechanisms of 
miRNA-mediated gene expression control, therefore reaffirming RPPA as an 
appropriate tool to investigate these regulations. 
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As previously suggested, assigning phenotypical functionality to a miRNA on the 
basis of a single strong effect on a target can be misleading and might not reflect 
the actual biological effects achieved intracellularly. Therefore, the HTS data was 
used to develop a novel network analysis approach to identify miRNAs that are 
able to affect the pathways of interest. 
 
3.5. Network analysis to unravel the role of miRNAs on complete pathways 
The network analyses here described were conceptualized by me and discussed 
with Astrid in depth. The analysis pipelines were entirely developed and ran by 
Astrid. 
 
3.5.1. Score development 
Two concepts proposed by me were the basis on which the analyses were 
developed in order to unravel the biological role of miRNAs: 
a) The extent of the miRNA-target regulation is not relevant in the network 
context, therefore only the information of whether the interaction is positive or 
negative is retained. 
b) The role that the targets investigated play within the pathway is fundamental 
information, as it contextualises the effect of the miRNA on the pathway. 
Therefore, the miRNA-dependent effect on the pathway as a whole is taken 
into account as subordinate to the role of the target on the pathway itself. 
 
Figure 3.4. WNT/β-catenin signaling pathway and the role of probed targets. The 
WNT/β-catenin signaling pathway is represented as available from KEGG pathways 
(Kanehisa, Sato et al. 2016). The target proteins probed in the RPPA screen are colour 
coded according to their role in the pathway. Protein edges which are activators or 
repressors of the pathway are marked in yellow or purple, respectively. 
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The WNT/β-catenin pathway is presented in figure 3.4 with a colour coding that 
represents the putative role of the proteins on the respective pathway, an 
information collected through the KEGG pathway database itself, as well as the 
GeneCards repository of the Weizmann Institute of Science. In supplementary 
figure 4, the KEGG pathways with the protein functions are shown for c-Met and 
Integrin signalling. 
 
Based on the hypotheses provided, we permuted the data matrix of significant 
log2FC to represent the putative effect of the miRNA on the pathway. 
Specifically, the log2FCs are transformed into a matrix of +/- 1 which reflects the 
effect of the miRNA on a target and in the meantime integrate in the matrix the 
role of the protein on the pathway itself (fig 3.5). This matrix therefore describes 
the putative miRNA-network (miR-N) effects. The term miR-N will be used further 
to identify this matrix. 
 
 
 
Figure 3.5. Data permutation. On the left, the heatmap of miRNA-mediated effects at 
the protein level is schematically represented (purple, significant upregulations; dark 
green, significant repressions). The colour of the protein columns (A-D) represents their 
role on the pathway investigated (light purple, repressing; light yellow, activating). The 
arrow represents the permutation which leads to the matrix of +1 (green) or -1 (bright 
red). The matrix as a whole is then exploited to compute the score which indicates a 
putative role for the miRNA in the same row (R, bright red, repressive; A, green, 
activator). 
 
Starting from the permuted matrix, we computed a Pathway Coregulatory (PC) 
score which represents the sum of the permuted interactions, divided by the 
number of targets in the pathway (fig 3.5). This last step is carried out in order to 
normalize the score and therefore render it comparable between the different 
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pathways analysed. Hence, the score represents the cumulative putative effect of 
each miRNA on the whole pathway. In figure 3.6 the distribution of the PC scores 
for the three pathways are shown. 
 
Of note, the WNT pathway has a more symmetrical distribution of PC scores 
compared to the other two pathways. This is probably due to the skewing of the 
biological role of the protein we probed, with the WNT pathway having 50% 
activators and 50% repressors probed. For Integrin and c-Met, the repressors 
represent only 9-16% of the probed targets. Since the majority of the significant 
effects identified in the HTS are downregulations, the PC score is biased toward 
repression. 
 
Figure 3.6. PC score distribution. The three panels show the distribution of the PC 
scores for the three separate pathways. In the x-axes the miRNAs are represented as 
ranked from the highest to the lowest PC score. On the y-axes the value of the 
respective PC score is represented. The ranking of the miRNAs is done pathway-wise. 
On the bottom right corner the box contains a brief description of the number of targets 
probed by pathway and the respective amount of activators or repressors of the 
pathway. The percentage in parenthesis specifies how many of the targets of the 
pathway belong to one or the other category. 
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Regarding the values of the PC score, the integrin pathway has longer tails with 
higher absolute values, compared to both the other two pathways. This is not 
simply due to the larger amount of proteins probed. Indeed, while in the integrin 
pathway there are more targets, the total amount of statistically significant 
interactions is lower than in the c-Met pathway, where only 30 were probed. By 
analysing the amount of interactions per protein, it is possible to see how within 
the integrin pathway, a smaller number of miRNAs affect single target. As a 
consequence, it seems that for the integrin pathway there is a higher coregulatory 
complexity which is reflected by higher PC score absolute values. 
 
To identify which miRNAs with a strong PC score are functional regulators, we 
proceeded to statistically validate the scores. 
 
3.5.2. Validation of the PC scores: Testing against a random distribution 
The randomization testing was proposed by me and discussed in depth with 
Astrid, who then developed and ran the pipeline. 
While the PC score represents still a putative effect on the pathway, there is the 
need to test for its robustness in statistical terms. Therefore, the matrix of 
permuted data is resampled 10’000 times/protein (fig 3.7). The actual PC score 
calculated with the data is then tested against the probability distribution of 
random PC scores and considered significant based on an alpha-level of 5% (p-
value ≤ 0.05). 
 
The distributions of random PC scores for two miRNAs which pass the 
significance threshold for the WNT/β-catenin pathway analysis are shown in 
figure 3.8. For miR-92b-3p it is possible to notice how the actual PC score (red 
vertical line) is lower than the negative threshold line, and therefore the miRNA is 
considered a negative regulator of the pathway. For miR-195, the actual score 
falls instead above the threshold, and therefore it is considered an upregulator of 
the pathway. 
 
The statistical validation revealed 46 putative repressors of WNT pathway, while 
only 4 miRNAs as possible upregulators. For the Integrin signalling pathway, 93 
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miRNAs were listed as putative repressors and 59 as activators. C-Met signalling 
pathway returned 113 putative repressors and 54 activators. 
 
Figure 3.7. PC score randomization. The randomization testing is schematically 
represented here. On the left side the miR-N matrix from actual RPPA data is 
represented. This matrix is permuted 10’000 to generate random PC scores (right side). 
The lower portion represents visually miRNAs (1-4, in black) and the randomized 
interactions with proteins (A-G, in white). 
 
 
Figure 3.8. Examples of random PC score distribution. The two graphs represent the 
cumulative distribution of the randomized PC scores for miR-92b (left) and miR-195 
(right). On the y-axis is depicted the density, on the x-axis the corresponding PC score. 
The vertical green dotted lines represent at which PC score value the miRNA would pass 
the alpha-level of 5%. The vertical red line depicts the actual PC score value for the two 
miRNA shown. In the graphs, the distribution is presented as smoothened. 
 
The list of miRNAs passing the statistical testing is listed for each pathway in 
Supplementary table 2.  
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3.6. Experimental validation 
The experimental validation of miRNAs ability to regulate whole networks was 
focused on the WNT/β-catenin pathway for four main reasons: 
 By means of a reporter assay for TCF/LEF transcription factors, the activity of 
the WNT/β-catenin pathway could be quantitatively investigated. 
 The RPPA HTS covered well both upregulators and downregulators targets, 
giving more confidence that the results would not be biased toward 
repressing miRNA-effects. 
 MDA-MB-231 cells activate the pathway by autocrine secretion of WNT7B. As 
a consequence, we assumed that identified miRNAs might be more relevant 
regulators of a pathway which is constitutively active (Huguet, McMahon et al. 
1994). 
 In TNBC the β-catenin pathway activation is regarded as a driver of 
metastatic pathological features (Dey, Barwick et al. 2013). However, 
members of this pathway do not seem to be altered at the genomic level, 
compared to other tumour types, such as colorectal carcinoma. Therefore, 
investigating the pathway was considered interesting in view of possible 
clinical applications that might stem from harnessing microRNAs repressing 
WNT/β-catenin signalling. 
  
To experimentally validate the interactions with a reporter assay, the DKFZ SiR 
core facility was requested to prepare a cell line which contains the firefly 
luciferase reporter gene under the control of six TCF/LEF responsive elements 
(CCTTTGWW, where W is an A or T) and therefore under the regulation of the 
WNT pathway activity. (fig 3.9). 
 
Five different clones were validated by stimulating cells with recombinant WNT3a 
as well as lithium chloride (LiCl) treatment (fig. 3.10). LiCl has been described to 
inhibit GSK3B, a kinase that phosphorylates β-catenin and promotes its 
ubiquitination and proteasome-mediated degradation (Stambolic, Ruel et al. 
1996). 
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Figure 3.9. Schematic representation of the reporter gene assay. When the pathway 
is not activated (upper panel), the firefly luciferase is not expressed. When cells are 
stimulated with recombinant WNT3a, β-catenin translocates to the nucleus and activates 
transcription of the reporter gene. Upon stimulation and miRNA OE, the luciferase 
expression should be reduced, at the condition that the miRNA is actually able to repress 
the pathway. 
 
 
 
Figure 3.10. Firefly luciferase response upon modulation of the WNT pathway. The 
five clones of stable isogenic recombinant cells were tested for responsiveness to the 
WNT pathway by stimulating with recombinant WNT3a alone or in combination with LiCl. 
Y-axis represents the signal intensities of firefly-induced luminescence, representing the 
activity of the enzyme. 
 
In the case of MDA-MB-231 it seems that inhibition of GSK3B does not give any 
additional benefit for activation of the pathway. The presence of a mild luciferase 
activity even when the cells are not stimulated is most likely due to the fact that 
MDA-MB-231 are able to activate the pathway by secreting their own ligand, as 
previously stated. 
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In order to avoid working with miRNAs which are likely irrelevant in the 
pathological context, their expression in breast cancer was analysed. miRNAs 
quantified at ≤10 RPKM in >95% of patients or with a median RPKM ≤ 5 in the 
TCGA Breast Cancer dataset were considered not expressed (TCGA data portal, 
see in materials>databases and online portals). These miRNAs have been 
marked in data tables with a suffix “_NE”.  
As second filtering step, the stability of the PC score was analysed by increasing 
thresholds for both q-values and log2FCs. PC values which remained stable in 
direction of regulation (i.e. positive or negative) indicated miRNAs considered 
more reliable in their effect on the pathway. This analysis was not further 
statistically tested; however, it was exploited as a guide when choosing which 
microRNAs to validate experimentally. In supplementary table 3, the PC scores 
calculated with increasing thresholds are listed (available on CD version due to 
size limitation). 
 
After expression selection, 19 miRNAs remained listed. On the basis of known 
literature and the PC score stability, 12 miRNAs were selected for experimental 
validation exploiting the reporter gene assay. 
  
Of the 12 miRNAs tested, six significantly downregulated reporter gene 
expression compared to a miRNA mimic control (fig. 3.11). On the contrary, two 
miRNAs strongly upregulated the signal. 
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Figure 3.11. Relative luciferase activity of the WNT reporter assay upon miRNA 
OE. On the y-axis, the relative luciferase activity upon WNT3a stimulation is represented 
as a fold change compared to the miRNA mimic control condition. Luciferase activity was 
measured 48 hrs post-transfection and 18 hrs post-stimulation. The green horizontal 
dotted line represents a downregulation of 20% in luciferase activity. Statistical 
significance against the control condition (red horizontal dotted line) was calculated with 
a two-tailed student’s t-test. P-values are represented with asterisks on top of the 
corresponding condition (** ≤ 0.01, *** ≤ 0.001). 
 
To further validate that the miRNAs are not affecting the luciferase signal by 
reducing the proliferation of cells, the six top repressing miRNAs were tested also 
in three independent clones of SiR which harbour a renilla luciferase 
constitutively expressed (fig. 3.12). 
 
As positive control for downstream experiments, iCRT14, a chemical inhibitor of 
nuclear translocation of β-catenin (Gonsalves, Klein et al. 2011), was tested on 
the reporter cell line to identify the concentration that would most likely resemble 
the change in the signal that was observed upon miRNA OE (fig 3.13). 
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Figure 3.12. Validation of miRNA-mediated repression of the WNT/β-catenin 
pathway. On the y-axis, the relative luciferase activity upon WNT3a stimulation is 
represented as a fold change compared to the miRNA mimic control condition. 
Luciferase activity was measured 48 hrs post-transfection and 18 hrs post-stimulation. 
The green horizontal dotted line represents a downregulation of 20% in relative 
luciferase activity. Statistical significance against the control condition (red dotted line) 
was calculated with a two-tailed student’s t-test. P-values are represented with asterisks 
on top of the corresponding condition (* ≤ 0.05, *** ≤ 0.001). 
 
 
Figure 3.13. Evaluation of chemical inhibition of the pathway. On the y-axis, the 
relative luciferase activity upon WNT3a stimulation is represented as a fold change 
compared to the control treatment (DMSO). On the x-axis the different iCRT 
concentration tested are plotted. The grey rectangle indicates the repression of the 
pathway that we aimed for, according to the effect exerted by miRNAs in the previous 
assays. 
 
Dissertation  Chiara Giacomelli 
 
 
 
88 
Considering that the target downregulation aimed for is similar to the one exerted 
by the strongest miRNA (miR-193b), working concentration for downstream 
assays was chosen as 10 µM. This concentration is in line with the one used to 
assess cell proliferation or invasion effects in breast cancer cells (Bilir, Kucuk et 
al. 2013, Zhang, Liu et al. 2017) or beta-catenin dependent transcription in colon 
cancer cells (Gonsalves, Klein et al. 2011). 
At low concentrations (<5 µM) the chemical inhibitor induced an upregulation of 
luciferase signal compared to the control-treated MDA-MB-231 (DMSO). This 
phenomenon wasn’t further investigated. However, a possible mechanism 
underlying this effect could be a feedback loop dependent on a mild repression of 
the transcriptional activity of beta-catenin. 
 
Concluding, of 12 miRNAs putatively affecting the WNT signalling pathway 
according to the network analysis, four were consistently able to repress the 
expression of a reporter gene under the control of six β-catenin responsive 
elements. Additionally, a chemical inhibitor (iCRT14) was tested to identify the 
appropriate concentration to mimic the effect of the miRNAs on the pathway-
dependent transcription. 
 
To visually summarize the miRNA:target interactions and their effect on the 
pathway, with the support of Astrid, a network was built (fig. 3.14). It is important 
to notice that the edges do not represent the direct miRNA:target effect. Indeed, 
the data used to display the network belongs to the miR-N matrix (fig 3.9). 
Therefore, the colours used are indicative of the putative effect of the miRNA on 
the pathway via interaction with the target protein. 
 It is possible to appreciate how the miRNAs which indeed affected the pathway 
have a high amount of significant interactions with the targets, supporting the 
hypothesis that a despite in a mild manner, many interactions are more relevant 
for the pathway regulation than a single, very strong, downregulation. However, it 
is imperative to recognize also that the four miRNAs that indeed affect the 
reporter gene activity (dark blue nodes) are connected to certain targets via 
activating edges (green). 
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Figure 3.14. Network of significant miRNA-target interactions within the WNT/β-
catenin signaling pathway. The network represents all the statistically significant 
interactions for those miRNAs which were tested for their ability to repress the reporter 
gene under β-catenin control. The legend on the upper left describes the colours for the 
edges and nodes shown in the network. The edges are colour coded based on the 
putative effect of the miRNA-target interaction that they are exerting, according to the 
permuted data table shown in figure 3.9. 
 
3.7. Functional role of miRNAs downregulating the WNT/β-cat pathway 
Of the 12 miRNA tested, miR-193b, miR-409, miR-494, and miR-92b were able 
to repress the expression of a WNT reporter gene, opening the question to 
whether they are able to affect also WNT-dependent phenotypes. One of the 
main phenotypical consequences of the activation of WNT/β-catenin pathway is 
proliferation, via induction of genes such as MYC, JUN, and cyclins. Moreover, in 
cancer the pathway has been frequently associated with EMT characteristics and 
maintenance of stem-like abilities. Therefore, phenotypes related to the pathway 
activation were hypothesized to be regulated by the four miRNAs identified via 
the reporter gene assay. 
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3.7.1. Proliferation 
Upon miRNA O.E. and pathway stimulation with recombinant WNT3a, three of 
the four selected miRNAs are able to significantly downregulate proliferation. 
Treatment of cells with the chemical inhibitor at 10 µM shows to which extent the 
phenotype is dependent on WNT pathway-induced transcription.  
 
Figure 3.15. miRNA-mediated effects on proliferation upon WNT pathway 
induction. Proliferation was measured counting nuclei upon miRNA OE, or iCRT14 
treatment by microscopy. The assay was performed at 76 hours and 100 hrs post-
transfection. The y-axis represents the fold change in nuclei count compared to the 
control (mimic negative control for miRNAs/DMSO for iCRT14). Statistical significance 
against the control condition was calculated with a two-tailed student’s t-test. P-values 
are represented with asterisks on top of the corresponding condition (* ≤ 0.05, ** ≤ 0.01, 
*** ≤ 0.001). 
 
While iCRT14, at the selected concentration, is able to reduce proliferation by 
roughly 70%, the best-performing miRNA, miR-193b-3p, represses proliferation 
up to 60% at 100 hrs post-transfection (fig. 3.15). The presence of a major 
phenotype which is independent from the regulation of WNT pathway seems to 
be the case also for miR-92b which upregulates proliferation, regardless of its 
repressive role on the WNT pathway. 
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3.7.2. Stemness 
To investigate the stem-like proprieties of MDA-MB-231 cells upon WNT pathway 
modulation, we proceeded to assay the expression of surface markers, as well as 
the ability of cells to overcome anoikis and grow in absence of attachment as 
spheres in miRNA gain-of-function assays. The hypothesis was that miRNAs 
downregulating the WNT pathway would be able to repress these stem-
associated phenotypes. 
 
3.7.3. Stem cell markers 
Four days after miRNA OE, cells were detached to proceed with FACS analysis 
of CD24 and CD44 surface markers. This experimental procedure was optimised 
in order to deliver the least damage possible to the surface markers. Detachment 
procedures tested were: trypsinization with solutions at 0.25% and 0.05%, 
scraping with 2%FBS in PBS solution, treatment with TrypLETM Express 
(Gibco®), or treatment with Cell Dissociation Buffer enzyme-free (Gibco®). The 
latter provided the same results as scraping with 2%FBS in PBS, while requiring 
shorter handling time for the samples. Therefore, it was used as method to 
detach cells prior to surface markers quantification. 
Quantification of the percentages of cells positively or negatively stained for the 
markers shows that miR-193b, as well as iCRT14, are able to significantly 
modulate the expression of CD24 and CD44. Indeed, both treatments significantly 
reduced the percentage of CD44+/CD24- compared to the respective control (fig. 
3.16.A). This result indicates that repression of WNT pathway is associated with 
the loss of stem-related surface markers. 
However, analysing populations stained for a single marker, it becomes apparent 
how the miRNA tends to affect mostly CD44 expression, increasing the 
percentage of the CD44 negative cells. On the contrary, the chemical inhibitor 
rather increases the percentage of CD24+ cells. (fig. 3.16.B). 
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Figure 3.16. miRNA-mediated control of stem markers CD44 and CD24. A The 
percentages of CD44+/CD24- cells are shown for control conditions as well as treated. 
B. Deconvolution of the data to assess the effect of the treatments on the individual 
markers. Percentages of CD44- and CD24+ cells are shown separately for all the 
conditions. Statistical significance against the respective control conditions was 
calculated with a two-tailed student’s t-test. P-values are represented with asterisks on 
top of the corresponding condition (* ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001). 
 
In conclusion, the results show that among the microRNAs which downregulate 
the expression of a WNT-dependent reporter gene, three are affecting 
proliferation of MDA-MB-231 cells, and one, miR-193b-3p is able to modulate the 
expression of CD44, a surface marker associated with stem-like properties. 
However, none of the miRNAs was able to regulate the formation of 
mammospheres. As well, iCRT14 was not affecting this phenotype. This possibly 
hints at the fact that while miR-193b and iCRT14 alone are able to modulate the 
surface markers, this is not enough to significantly reduce the stem-like content of 
the MDA-MB-231 cell population and therefore it does not affect the growth of 
spheres in ultra-low attachment conditions. 
 
3.8. Validation of direct control of gene expression by microRNAs 
Of the miRNAs tested for their effect on the WNT/β-catenin signalling pathway, 
three were shown to be strong regulators of proliferation in the context of 
pathway activation. The role of these miRNAs on the pathway was inferred by the 
target protein regulation. However, to fully understand the molecular mechanism 
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underlying the phenotype, it is necessary to investigate the direct interactions 
miRNA:mRNA. 
 
This can tested via a reporter gene assay where the 3’UTR of the putative target 
genes is cloned downstream of a luciferase gene. In this manner, the luciferase 
activity will be a proxy to understand if the candidate miRNAs are binding to the 
3’UTR of the putative target genes. 
TargetScan v7 database was queried for putative MBS on the 3’UTR of the 
genes belonging to WNT pathway. Nine out of 14 genes contained predicted 
MBS in their 3’UTRs, therefore these sequences were cloned downstream a 
renilla luciferase reporter gene, either full, or in portions when longer than 1.5 kB 
(fig. 3.17). miRNAs and the vector harbouring the reporter genes were transiently 
transfected in MDA-MB-231 and 48 hrs later luciferase activities were assayed 
(fig. 3.18). 
 
The results shown in figure 3.18 clearly show that miR-193b is able to 
significantly downregulate the expression of the reporter gene in all cases, while 
miR-494 represses only of LRP6- and PSEN1-3’UTR harbouring reporter genes. 
Intriguingly, despite being predicted to have multiple MBS on various genes, miR-
409 did not significantly affect any of the cloned 3’UTRs. This is highly consistent 
with the fact that in our RPPA data we found that the majority of the targets were 
upregulated upon miR-409 OE, hinting at the fact that this miRNA might affect the 
pathway indirectly through targets not yet identified. These results confirm that 
the interactions predicted for this miRNA are not functional in our cell system, as 
it is not able to repress reporter gene expression. As well, they tell a word of 
caution about using MBS prediction as definitive tool to estimate computationally 
the biological role of a miRNA: they always need to be proved within the context 
in use. Additionally, the presence of a functional 6mer which was not predicted 
(miR-193b on CTNNB1), indicates that in certain cases the available prediction 
tools are not enough to identify actual interactions. 
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Figure 3.17. Schematic representation of genes of interest and cloned sites. Each 
gene of interest is shown, with the transcript ID used to retrieve the 3’UTR sequences as 
well as their length. Coding region is in black and the UTRs are in white, while the grey 
areas correspond to the cloned portions of the UTRs. The vertical bars represent the 
predicted miRNA binding sites, colour coded by miRNA. The predicted binding sites are 
further represented as nucleotide sequences with a colour coding that identifies the type 
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of binding site. In three instances, the binding sites are rated as conserved by TS v7. 
The first miR-193b site in LRP6 is a non-canonical binding site termed “centered site” 
(coded in light green). In the bottom right of the figure, the miRNA binding sites are 
represented as (Baek, Villen et al. 2008). The colour coding of the binding site type is 
used to mark the miRNA binding site in all the nucleotide alignment shown. 
 
 
Figure 3.18. miRNA targeting 3’UTRs of interest. Normalized luciferase activity is 
shown for all the 3’UTRs that were predicted to be targeted. Statistical significance 
against the respective control conditions was calculated with a two-tailed student’s t-test. 
P-values are represented with asterisks on top of the corresponding condition (* ≤ 0.05, 
** ≤ 0.01, *** ≤ 0.001). 
To elucidate whether miRNA:mRNA interaction is directed specifically toward the 
predicted binding sites, the three nucleotides corresponding to the seed match 
positions 3 to 5 in each of the significantly downregulated 3’UTRs constructs 
were mutated. The mutation should disrupt the matching of the miRNA to its 
binding sites and rescue the expression of the reporter gene (fig. 3.19) 
 
For miR-193b, mutations of the 3’UTR binding sites rescued the expression of 
the luciferase only for three genes out of seven interactions. In the case of 
PSEN1, it seems that the first binding site is the only functional one. However, 
when both were mutated the rescue is stronger, hinting at a possible 
cooperativity between the two sites. This was not the case for APC, where it 
seems that not the single mutations, nor the double, are able to rescue the 
expression of the reporter gene. Regarding the mutations of miR-494 predicted 
binding sites, there is a trend in re-establishing the expression of the reporter 
gene. However, these changes are not statistically significant. 
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Figure 3.19. Validation of the reporter gene repression as direct at the 3’UTR. 
Normalized luciferase activity is shown for all the 3’UTRs that were predicted to be 
targeted and that were repressed in a WT condition. Statistical significance for the WT 
constructs was calculated against the control condition (black asterisks). Statistical 
significance for the mutated constructs was instead calculated against the WT 
counterpart (green asterisks). P-values are represented with asterisks on top of the 
corresponding condition (* ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001).  
The inability to rescue the expression of the reporter gene can be explained in 
different ways. First it could be that mutating the three nucleotides corresponding 
to 3 to 5 seed position is not enough to disrupt the miRNA-target interaction. 
Additionally, there could be functional but non-canonical miRNA binding sites in 
the 3’UTR of interest which have not been identified. Nevertheless, whether the 
interactions are direct on the 3’UTR or not, both miR-193b and miR-494 were 
shown to be highly integrated in the WNT/β-catenin signalling network. 
 
In conclusion, in collaboration with Astrid, we described interactions between 800 
microRNAs and 62 targets belonging to three pathways relevant for breast 
cancer metastasis. These interactions were evaluated at the protein level, 
therefore increasing the confidence in their biological function. By means of a 
novel network approach which takes into consideration the context of each 
miRNA-target interaction by integrating the information of the role of each protein 
on the pathway to which they are associated, Astrid and I were able to identify 
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miRNAs putatively affecting c-Met, Integrin signalling, and WNT β catenin 
pathways. 
Considering the pathological relevance of WNT pathway and the possible clinical 
exploitation of results of miRNA that inhibit it, the focus of the project shifted to 
this pathway for the experimental validation. Four miRNAs were characterised as 
strong regulators of the pathway, significantly affecting β-catenin-dependent 
transcription. Of these, three were able to repress proliferation. One of these was 
also able to affect stem cell surface signatures. However, none of them was able 
to affect mammosphere formation in low attachment conditions. In this assay, the 
chemical inhibitor iCRT14 was also ineffective. This put into question whether the 
phenotype is indeed dependent on the WNT pathway in the cell system in use. 
Of the three miRNAs phenotypically affecting proliferation, analysis of the direct 
binding at the 3’UTR of target genes was performed. Results at the reporter gene 
level recapitulated the extent (in FC) the repressions discovered by RPPA. 
However this did not happen for miR-409, hinting at the fact that the upregulation 
of proteins measured is indeed indirect and not mediated by interaction with the 
3’UTRs of corresponding predicted genes. miR-409 inability to repress the 
reporter in the assay also point out at how predicted miRNA binding sites might 
actually not be functional upon testing. 
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4. Discussion 
 
The primary aim of the project was to identify novel miRNAs regulating signalling 
pathways relevant for the metastasization and stem-like abilities of triple negative 
breast cancer. The project began by selecting pathways of interest for the type of 
cancer and the cell line model used. Subsequently, target genes belonging to c-
Met, Integrin, and WNT/β-catenin signalling pathways were chosen, and their 
expression analysed in the cell model. The effect of miRNAs on the 
corresponding proteins was analysed by means of RPPA. Selecting a very 
stringent statistical threshold, miRNAs were scored for their putative effect on the 
selected pathways with a novel network approach. In this analysis, the 
fundamental information regarding the role of the targets quantified was included 
to contextualise the effect of the miRNAs. The score was then tested against a 
random population upon resampling miRNA-target interactions, identifying 
multiple miRNAs that would regulate each pathway. 
 
The WNT/β-catenin pathway was chosen to prove experimentally that the 
identified miRNAs indeed regulate its activity. Exploiting a reporter gene assay, 
four miRNAs were validated as as strong repressors of the pathway. Of these, 
three were able to reduce cell proliferation in a context of pathway overactivation. 
Analysing the direct miRNA-target interaction by means of a 3’UTR reporter 
assay, the molecular interactions were validated, proving that the identified 
miRNAs are remarkably highly integrated in the WNT/β-catenin pathway. 
 
4.1. C-Met, Integrin, and WNT/β-catenin pathway choice 
The choice of the pathways of interest started by assessing what type of triple 
negative breast cancer is modelled by MDA-MB-231 cells, since this was the 
system in which the miRNA library was overexpressed. To reach biologically 
relevant conclusions, the focus of the project was on pathways enriched in the 
subtype represented by the cell line in use. The classification of TNBC patients 
that was developed by Lehmann and colleagues was used as a basis for the 
pathway choice. In a seminal study from 2011, they classified TNBC patients in 
sub-subtypes on the basis of unsupervised clustering of their gene expression 
profiles. Then, gene expression data of TNBC cell line models was matched with 
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the profiles identified in patients. MDA-MB-231 cells fell into the category defined 
by Lehmann and colleagues as Mesenchymal Stem Like (MSL) (Lehmann et al, 
2011, JCI). The six subtypes have been refined into four groups (BL1, BL2, M, 
and LAR) upon assessment of the stromal component of the tissues analysed. In 
the same study, TNBC cell line models have been reclassified, with MDA-MB-231 
cells established as a model for the BL2 subtype.  This subtype exhibits the 
lowest pathological complete response rates among all subtypes, making it an 
important biological entity to further investigate (Lehmann, Jovanovic et al. 2016).  
 
Among the pathways enriched in the MSL subtype in the original paper, WNT/β-
catenin, integrin mediated adhesion, and focal adhesions attracted my attention 
for their well-known association with metastatic phenotype and stem-like 
characteristics. Additionally, the increased evidence of the role of c-Met on basal 
breast cancers as well as its possible druggability made it an interesting subject 
of investigation. Notably, in various pathological and physiological conditions, the 
three pathways were found highly interconnected. In hepatocytes, HGF was able 
to induce Wnt-independent nuclear translocation of β-catenin (Monga, Mars et al. 
2002). In colon cancer, WNT and MET pathways have been shown to cooperate 
to maintain the niche where cancer stem cells are residing (Vermeulen, Melo et 
al. 2010). In the same context, it was shown that MET is under the transcriptional 
control of TCF4 and therefore can be modulated by WNT signalling pathway 
(Boon, van der Neut et al. 2002). One of the canonical downstream arm of c-Met 
signalling is the CDC24/RAC, which in turn signals toward cadherins and 
integrins. Additionally, in breast cancer metastatic processes and in glioblastoma 
invasion, it was shown that c-Met dimerizes with integrin β1, displacing it from the 
complex with integrin α5 (Jahangiri, Nguyen et al. 2017). These findings, albeit 
mostly in tissues different than breast, might indicate a strong connectivity with 
functional relevance for the metastatic cascade and encourage further 
investigations.  
 
4.2. RPPA identifies many mild miRNA-mediated protein changes 
Many studies now have addressed the impact of microRNAs on protein levels 
both via mass spectrometry- (MS) or protein-based assays, however, this is one 
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of few in which the focus of the study are specific pathways of interest chosen a 
priori. 
While MS techniques coupled to SILAC or pSILAC are unbiased and able to 
address general questions related to miRNA biology, they have a lower 
throughput when it comes to amount of conditions that can be simultaneously 
investigated (Baek, Villen et al. 2008, Selbach, Schwanhausser et al. 2008). 
Indeed, the majority of MS-based approaches have been used to define the basic 
biological rules that define direct miRNA-dependent effects. While confirming that 
the predominant way a miRNA identifies and regulates its targets is based on the 
seed sequence, as well as claiming that the MBS with higher complementarity 
are more efficiently exerting this role, no analysis regarding the networks of 
protein affected by the miRNA was performed. MS-based approaches have also 
shown that the average effect of miRNA gain-of-function on targets which contain 
at least a seed sequence binding site in their 3’UTRs is mild, ranging from around 
-0.3 to -0.5 log2FC (Baek, Villen et al. 2008, Selbach, Schwanhausser et al. 
2008). In the context of ER+ breast cancer, mass spectrometry coupled with 
iTRAQ (isobaric tag for relative and absolute quantification) was exploited to 
identify in an unbiased fashion the targets of miR-193b at the protein level 
(Leivonen, Rokka et al. 2011). Analysing also gene expression upon miR-193b 
OE, they also showed that only a minority (13%) of the proteins identified had a 
matched repression of its mRNA molecule (Leivonen, Rokka et al. 2011). 
 
In comparison to MS-based techniques, protein array-based technologies allow 
researchers to understand the impact on specific targets of many more miRNAs, 
thanks to the high sample-content and sensitivity. This approach has been now 
adopted with success numerous times to identify protein expression regulated by 
miRNAs in a “genome-wide” manner, by overexpressing libraries representing 
the known miRNome (Leivonen, Makela et al. 2009, Uhlmann, Mannsperger et 
al. 2012, Leivonen, Sahlberg et al. 2014, Moss, Luo et al. 2015). In most of the 
cases, the regulatory activity of a miRNA on a pathway was taken into account by 
probing few genes that should suffice to describe activation of the respective 
pathway, such as HER2, Ki67, cleaved PARP, phospho-AKT, and phospho-
ERK1/2 as proxies for the entire HER2 pathway (Leivonen, Sahlberg et al. 2014). 
Few studies have taken into consideration larger numbers of targets, the most 
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numerous being a screening of 879 miRNAs on 127 targets in 3 cell lines (Moss, 
Luo et al. 2015). Based on this data, Moss and colleagues defined miRNAs to be 
functionally integrated in a pathway when they would modulate the expression of 
at least 50% of the probed protein from that pathway (Moss, Luo et al. 2015). 
However, except for the identification of miRNAs specifically affecting the EGFR-
driven cell cycle (Uhlmann, Mannsperger et al. 2012), none of the currently 
available datasets specifically focuses a priori on a pathway as a whole. With the 
aim to identify as many miRNA as possible that could target specific pathways 
that are of clear clinical relevance, we proceeded by exploiting RPPA. This gave 
two main advantages: very high sample content, coupled with analysis at the 
proteomic level. 
 
A main limitation of high-throughput screenings such as the one undertook in this 
PhD project and the ones of Uhlmann and colleagues, and Moss and colleagues, 
is the use of a library of miRNAs. Generally, libraries are constructed on available 
databases. Indeed, the library used in both this project and the EGFR pathway 
analysis (Uhlmann, Mannsperger et al. 2012) was developed on the miRBase 
database in version 10, corresponding to the release of 2007. This library 
contained 810 annotated miRNAs. Of these, 10 were considered “dead” (i.e. 
characterized later on not as miRNAs but as fragments of other longer RNA 
molecules) in the latest version of miRBase (v.21). While these were excluded 
from any analysis within this project, it cannot be ruled out that other of the 
annotated miRNAs will be, in the future, characterized as “dead”. Analysis of the 
library used for the presence of miRNAs identified as “High confidence” 
(Kozomara and Griffiths-Jones 2014) showed that more than 50% (448) are high 
confidence. Additionally, in the project, miRNAs not expressed in breast cancer 
tissues were excluded from validation, possibly preventing the inclusion of such 
“dead” molecules in downstream analyses. 
  
To identify significant miRNA-target interactions, we did not utilize the z-score. 
The choice of the limma test for this purpose stems from the experimental setup. 
Indeed, the setup is roughly limited to 650 samples per slide printed. Due to the 
presence of control samples, and two biological replicates for each miRNA 
transfection, the total of samples required to be divided into four subgroups 
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(termed arrays) to be probed. In turn, the data produced in such manner would 
have required the z-score to be calculated within each subgroup, to be a 
statistically appropriated method. 
However, distribution of the signal intensities for the same target varied between 
the different subgroups. While not tested, this phenomenon was hypothesized to 
be dependent on the non-random distribution of samples that would cause many 
miRNAs belonging to the same family to be spotted within the same array. 
Indeed, miRNAs of the same family (i.e. with the same seed sequence) should in 
principle share some targets. Therefore, they could affect en masse the signal of 
these targets and shift the distribution of the data for the whole array. Since the z-
score depends on the average and standard deviation of the distribution to define 
the individual sample value, in the context of this screening, its use might mask 
true interactions. For this reason, Astrid Wachter chose the limma test to 
calculate the statistical significance and the log2 FC against the miRNA mimic 
negative controls, possibly preventing the bias that could otherwise have 
stemmed from the use of z-score. Additionally, the limma test calculates the 
values taking into account the two biological replicates which were spotted, 
making the results statistically more robust. 
 
By means of the limma test, a high amount of miRNA-target interactions (5’435 
out of 49’600, ~11%) were identified with strong statistical significance (q-value ≤ 
0.001). Of these, 70% are downregulations (3804) and 30% upregulations 
(1631). Target-wise analysis revealed an average of 61 miRNAs repressing and 
26 upregulating, with the extremes being EGFR repressed by 190 miRNA and 
CDKN1B upregulated by 224. The distribution of miRNAs regulating single target 
didn’t seem dependent on whether the protein has an activating or repressive 
function on the pathway. It is tempting to speculate that proteins whose mRNA 
harbours a longer 3’UTR are more likely to be repressed by miRNAs. However, 
the correlation between length of 3’UTR (from TS v7) and amount of regulating 
miRNAs in the data gathered did not support this hypothesis. Indeed, there was 
no positive correlation between the miRNAs significantly downregulating a target 
and the length of the relative 3’UTRs. As for all analyses that exploit publicly 
available datasets, it is not possible to rule out whether, upon investigation of 
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3’UTR sizes specifically in MDA-MB-231 cells, results could instead support the 
hypothesis. 
  
Similar to previously reported data, the average negative effect on the expression 
of target proteins was -0.52 log2FC (corresponding to roughly 30% in protein 
expression). Indirect positive effects exhibited an average of 0.45 log2FC. To 
understand whether the identified regulations are mediated by predicted binding 
sites within the 3’UTRs of target genes, an enrichment test was performed, 
interrogating separately the downregulations, as well as the upregulations, which 
would serve as in internal control. The test returned 45% of the targets to be 
enriched in predictions of conserved miRNA binding sites in their 3’UTR, as 
shown in table 3.1. Non conserved (NC) binding sites presented a lower 
percentage of protein with enrichment, consistently with previous reports (Baek, 
Villen et al. 2008, Uhlmann, Mannsperger et al. 2012), probably indicating how 
predicted NC sites are less likely to be functional. MicroCosm Targets (MCT) 
returned a much lower percentage of significant enrichments. Considering that 
MCT allows in its prediction algorithm seed mismatches as well as single GU 
wobble pairs, the results suggest that its inability to perform as well in the dataset 
indicates how these predicted interactions might be less functional in 
downregulating protein expression. In comparison to the results of the Uhlmann 
screening (Uhlmann, Mannsperger et al. 2012), a lower percentage of targets 
presented significant enrichment. Indeed, in the EGFR pathway screening, 18 out 
of 25 (72%) targets passed the significance threshold, computed with a 
Kolmogorov-Smirnov (KS) test. This test was not used in this screen due to the 
nature of the limma analysis method that we exploited to measure miRNA-
dependent protein expression changes. Being the KS a threshold-free, rank-
based test, Astrid Wachter deemed inappropriate to use it on q-values which 
were generated with multiple limma tests applied on the 34 rounds of 
transfections separately. While this difference in analysis could be a reason for 
the lower percentage of targets presenting enrichment, upon closer inspection we 
can recapitulate 15 of the 17 significant enrichments identified in the Uhlmann 
screen (MIG-6/ERRFI1 was not probed). When comparing the results, we should 
not forget that the limma method returned as significant also very small protein 
modulations (e.g. miR-526b-5p repressing CSNK2B -0.08 log2FC). Such small 
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variations were not considered significant when their z-scores were statistically 
tested in the EGFR-pathway screening. 
 
A small percentage (9.7%) of targets presented significant p-values for 
enrichment also for the upregulations. This could be indicative of the fact that the 
prediction databases contain a number of false-positives that are not 
recapitulated in experimental conditions. In support to this hypothesis, albeit in a 
small scale which cannot explain effects on the whole screening, miR-409 might 
serve as example. Indeed, it presented many predicted interactions with 3’UTRs 
of genes of the WNT/β-catenin signalling pathway. However, luciferase assays to 
evaluate their functionality did not validate any of the interactions. 
It remains an open biological question whether miRNAs target possible binding 
sites also in the coding sequence of genes or 5’UTRs, and whether they are 
functional. As well, it is important to keep in mind that the type of enrichment test 
performed is based on 3’UTR sequences retrieved in publicly available datasets 
(TS uses UCSC genes, MCT is based on the ENSEMBL gene repository). 
However, intrinsic variabilities of 3’UTRs (SNPs, alternative polyA sites) could be 
at play in this type of post-transcriptional regulation, affecting the results of 
enrichments, as well as the biological effect of the miRNAs of interest (Fu, Sun et 
al. 2011). 
 
To conclude, the patterns of protein expression changes that we identified upon 
miRNAs OE are concordant to literature and to the known biological functions of 
miRNAs on their target. Additionally, we acknowledge that we are taking into 
account for downstream analysis, not only direct miRNA-target interactions, but 
indirect upregulations and downregulations as well. This fact is consistent with 
the purpose of the project to describe the role of miRNAs on complete pathways. 
 
4.3. Computation of scores to predict the role of miRNAs on the whole 
pathway. 
A main concept that was at the basis of the network analysis developed in 
collaboration with Astrid Wachter was that the context of a particular miRNA-
target interaction is biologically more relevant than the extent of the regulation 
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caused by the same specific miRNA. Therefore, the analysis addressed the 
possibility that a miRNA affecting multiple targets, yet mildly, might still strongly 
regulate a pathway when analysed as a large system. Given that pathways are 
constituted of proteins that themselves have a functional role within the pathway 
itself, it seemed natural to consider this factor in the downstream analysis. For 
the purpose of modelling, for each protein a single function (either positive or 
negative) was taken into account. Hence, the role of the miRNAs on each target 
was permuted into a putative effect on the pathway, by substituting the log2FC 
with a +1/-1 value which would be dependent on the role of the target as well as 
the direction of the regulation exerted by the specific miRNA. 
 
At this step of the analysis the extent of the regulation (log2FC) was arbitrarily 
disregarded and only strongly statistically significant interactions (q-val≤0.001) 
were taken into account. This choice was proposed by me and discussed 
together with Astrid Wachter to reach a conclusion we both would agree on. Two 
main reasons drove the decision: 
a) To actually infer quantitatively the role of a miRNA on the pathway, it would 
have been required to first quantitatively evaluate also the role of the protein 
on it. 
b) being the hypothesis that multiple small regulations are effective than few 
strong ones, the extent of the regulation of individual miRNA-target pairs was 
deemed not relevant. 
 
This decision seems to have been appropriate, on the basis of experimental 
validation of miRNAs which affect the WNT/β-catenin signalling pathway. 
Inspecting miRNA-target interactions in RPPA data, we can appreciate that miR-
19a-3p was strongly downregulating CTNNB1 and LRP5 (-0.93 and -0.42 log2FC 
respectively). This repression did not result in the ability of the miRNA to regulate 
the reporter gene response. On the contrary, miR-193b-3p influenced the 
expression of multiple targets in a mild manner (n = 10, -0.72 to -0.19, ave. -0.44) 
and was able to repress the reporter gene, as well as phenotypes downstream 
the WNT/β-catenin signalling pathway. Additionally supporting the decision, we 
can interrogate the PC scores calculated with increasing thresholds for the 
log2FC. Indeed, when we had taken into account a cutoff of │0.5│ log2FC, miR-
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409-3p score indicated a role for this miRNA as positive regulator of the pathway, 
whilst the reporter gene assay confirmed it as a repressor. To take into 
consideration the log2FCs a possible solution could have been to multiply their 
values for -1 or +1, in case the target protein was a repressor or an activator, 
respectively. In this scenario, the PC score would have probably not represented 
once more the effect on the pathway. Indeed miR-181d would have been the 
strongest repressor with a value of -1.57, and miR-409 the weakest with -0.15. 
Instead, the first was unable to affect the reporter gene and the latter repressed 
the reporter gene consistently. 
 
Therefore, the choice to disregard the log2FC information to compute the score 
was deemed appropriate. As well, it appeared that the randomization test was a 
feasible strategy to identify miRNAs modulating the pathway defined a priori. 
 
Still, some miRNAs identified with the PC score randomization method did not 
affect the reporter gene assay, suggesting possibly that additional filtering steps 
to refine the list of candidate miRNAs are required. Reasonable strategies could 
include i.e. the exclusion of miRNAs which target less than 50% targets probed 
within the pathway, as applied by TJ Moss and colleagues (Moss, Luo et al. 
2015). Higher pathway coverage via RPPA could also have provided a broader 
picture. Clearly, the availability of antibodies with enough specificity and 
sensitivity is a fundamental limit to the possibility of analysing consistently full 
pathways. Possibly, refined modelling strategies could have includes in the 
network analysis unknown variables corresponding to the unprobed (but 
expressed) proteins. 
 
4.4. miRNAs modulate  WNT/β-catenin signalling pathway activity. 
The role of the miRNome on the WNT/β-catenin signalling pathway had been 
previously studied by Anton and colleagues upon transfecting single miRNA in 
HEK293T cells together with a TOP/Flash reporter (Anton, Chatterjee et al. 
2011). Upon identification of the 12 miRNAs candidates from our screening, the 
results were compared with the ones identified by Anton and colleagues. miR-
193b, miR-409, and miR-28 were all described as mild repressors of the reporter 
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gene. On the other hand, miR-181d was characterized as activator. Whilst in 
MDA-MB-231 miR-193b and miR-409 downregulate the signalling pathway as 
well, neither miR-28, nor miR-181d were able to regulate the reporter gene. 
Some experimental differences could partially explain the results: e.g. Anton and 
colleagues transfected miRNA mimics at 40nM, possibly rendering the screening 
more prone to off-target and indirect effects when compared to the 25nM 
concentration used in the RPPA screening. However, an important message lies 
under these divergent results: within a cell system, the presence or absence of 
specific transcripts, as well as their abundance can deeply affect the role of a 
miRNA. Therefore, while supporting some of our findings, the screening from 
Anton and colleagues raises the issue that the effect of miRNAs should be 
considered in the cell type or tissue of interest. 
 
4.5. miRNAs regulate phenotypes dependent on the WNT/β-catenin 
signalling pathway. 
While validating the role of miRNAs on phenotypes that are dependent on the 
WNT/β-catenin pathway, the chemical inhibitor iCRT14, specifically designed to 
prevent CTNNB1 interaction with TCF7L2, thus blocking β-catenin dependent 
transcription, was exploited as positive control. First, iCRT14 was titrated using 
the reporter gene assay to define which concentration would resemble the most 
the effect seen with miRNA OE. This concentration (10 uM) was then used in all 
downstream assays. 
The four miRNAs which were able to regulate the expression of the reporter gene 
in the dual reporter assay were tested for their ability to modulate proliferation in 
a cell context in which the WNT pathway is overstimulated with recombinant 
WNT3a. miR-193b repressed proliferation by 60%, almost as much as iCRT14 
(75%). miR-409 and -494 repressed proliferation only by roughly 15%. The effect 
mediated by these miRNAs has been previously characterized in multiple tumour 
types, including triple negative breast cancer (for miR-193b and miR-494). Of 
note, miR-494 was described as repressor of WNT signalling in Pancreatic Ductal 
Adeno Carcinoma, where it was also able to repress proliferation and tumour 
growth in vivo (Li, Li et al. 2014). Additionally, the role of miR-494 on the WNT/β-
catenin signalling pathway has been previously characterized in TNBC, however 
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it was explained as dependent on its ability to repress the expression of CXC4 
(Song, Liu et al. 2015). Still, it has not been reported before that these miRNAs 
could repress cell proliferation under a condition of WNT/β-catenin pathway 
activation in triple negative breast cancer, such as in this case. 
 
Of the four candidate miRNAs, miR-92b strongly induced proliferation (+45%). 
The role of this miRNA has been reported in various cellular contexts with 
controversial results. Indeed, it represses proliferation and induces apoptosis in 
glioma (Wang, Wang et al. 2013). As well, it is correlated with DFS in breast 
cancer, where its higher expression is associated to better prognosis (Smith, 
Baxter et al. 2015). On the other hand, it has been shown that in HCC miR-92b 
not only enhances proliferation, but it is able to induce β-catenin localization in 
the nucleus and activation of its target genes (Zhuang, Yang et al. 2016). It is 
therefore intriguing to see contradictory results in MDA-MB-231 cells, suggesting 
that in this case the repression of WNT pathway is uncoupled from the pro-
proliferative effect. 
 
Different effects of miR-193b and iCRT14 were also detected via FACS analysis 
of surface markers of MDA-MB-231 cells. Expression of CD44 and CD24 has 
been used to define a population of “cancer stem cells”, termed also “tumour 
initiating cells”. MDA-MB-231 cells displays at the basal level an extremely high 
CD44+/CD24- population (>95%) (figure 3.16 and (Ricardo, Vieira et al. 2011)).  
Upon miRNA OE, the predominant effect detected was on the CD44+ population. 
In contrast, iCRT14 was able to increase the CD24+ population. Of note, CD44 is 
a direct transcriptional target of β-catenin. Therefore, it is tempting to speculate 
that in MDA-MB-231 miR-193b has a stronger ability than iCRT14 to regulate 
transcription dependent on β-catenin. However, to prove it, targeted experiments 
should be designed to compare transcriptional activity dependent on nuclear β-
catenin. In alternative, it is possible that the phenotype induced by miR-193b is 
dependent not only by the repression of the WNT/β-catenin pathway activity. 
 
In an attempt to define the effect of miR-193b, miR-409, and miR-494 on the 
stem-like phenotype of the cells, the ability of cells to survive anoikis and grow in 
clonal colonies was tested. First of all, no increase in sphere formation was 
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observed upon WNT3a stimulation of MDA-MB-231, as well as no reduction upon 
treatment with iCRT14. Additionally, none of the miRNA tested significantly 
affected the formation of spheres. Therefore, it seems that in this cell line the 
phenotype is not dependent on an additional stimulation of WNT pathway, 
possibly due to the already very high content of stem-like cells (Ricardo, Vieira et 
al. 2011). However, it was surprising not to see an effect caused by the WNT 
pathway inhibitor, suggesting perhaps that cells in which the pathway is inhibited 
cannot survive and are therefore negatively selected during the growth process. 
Experiments that allow for conditional tagging of cells (i.e. with a fluorescent 
protein under the control of WNT pathway) could perhaps support the hypothesis 
that only the cells retaining the pathway activity are the ones able survive low-
attachment conditions. 
 
Another method to assess the stem-like content of a population is the ALDEfluor 
assay, which identifies cells which express at high levels aldehyde 
dehydrogenase (ALDH), a feature characteristic of stem cells. The cell line model 
in use for this project, MDA-MB-231, was shown multiple times to exhibit a very 
low percentage (<2%) of of ALDH+ cells (Charafe-Jauffret, Ginestier et al. 2009, 
Marcato, Dean et al. 2011, Ricardo, Vieira et al. 2011). This finding is highly in 
contrast with the percentage of stem-like population that is widely described for 
MDA-MB-231 when determined by surface markers (Ricardo). In the context of 
this project is therefore clear that the use of ALDH+ cells as indicator of stemness 
might not be a feasible option.  Indeed, being the hypothesis that the identified 
miRNAs reduce the stem capabilities of the cells they are transfected in, such 
assay in MDA-MB-231 would provide a dynamic range very ineffective. However, 
a recent publication dissected the role of miRNAs as bimodal switches of breast 
cancer stem cell fate by means of a miniaturized ALDEFLUOR assay in SUM159 
cells (TNBC). In the screening, the authors focused on miR-600 as the top 
scoring miRNA which modulates WNT signalling via repression of SCD1. 
However, among the miRNAs identified in their screening, miR-193b was found 
as a very mild regulator of the phenotype (El Helou, Pinna et al. 2017), perhaps 
supporting its role as stem cell regulator in TNBC via WNT/β-catenin pathway 
modulation. Experiments to replicate the effects of miR-193b in additional TNBC 
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cell lines such as SUM159 should definitely be performed within this project to 
validate its role as suppressor of stem-like phenotypes. 
 
4.6. The identified miRNAs regulate WNT/β-catenin directly and indirectly 
pathway. 
In order to understand whether the interaction of a miRNA is direct, the golden 
standard experiment is to perform a reporter gene assay using the 3’UTR 
downstream of a reporter gene. This is ideally done maintaining the molecular 
context, i.e. by cloning the entire 3’UTR and not simply the predicted binding site. 
Indeed, it is now well understood that the position and the surrounding of the 
MBS can influence its functionality (Bartel 2009). Upon co-transfection of a 
miRNA mimic and the construct harbouring the reporter gene and the desired 
3’UTR, the reporter gene expression should decrease in presence of a direct 
interaction. To prove that the interaction is strictly dependent on the binding site 
predicted, it is possible to mutate some of its nucleotides, in order to disrupt the 
interaction. 
 
The three miRNAs that repress proliferation of MDA-MB-231 were analysed for 
their effect on the 3’UTRs of mRNAs encoding the targets that had been 
investigated via RPPA. The online prediction tool TS v7 was queried for MBS of 
the three miRNAs on the genes of the WNT signalling pathway. Additional 6-mer 
binding sites that are not predicted by the TS v7 were searched manually on the 
3’UTRs (figure 3.15). Several of them were identified within the 3’UTRs of 
CTNNB1 and CDH1. 
 
For miR-193b and miR-494, the reporter assays confirmed a strong molecular 
integration within the WNT/β-catenin signalling pathway. Indeed, CTNNB1 and 
LRP6 were identified as direct targets for both miRNAs. An interesting hypothesis 
to explore further is that the two miRNAs cooperate on the same 3’UTRs to 
repress in concert the expression of two of the pivotal players of the pathway. 
While the hypothesis was tested, the assay wasn’t optimised yet to appropriately 
evaluate the effects. The 3’UTR reporter gene assay additionally defined 
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CTNNBIP1, APC, and PSEN1 as direct targets of miR-193b, indicating how this 
miRNA has indeed a very strong integration within the pathway. 
 
With regards to the 6mers manually identified the binding sites on CDH1 where 
not functional upon miR-494 OE, while the BS for miR-193b on CTNNB1 strongly 
repressed luciferase expression, proving their functionality. Despite the short 
complementarity between the BS and the miRNA, in this case it seems that the 
context is of outmost importance. Indeed, it is positioned very close to the end of 
the CDS, a location very well characterized for its efficacy (Bartel 2009). 
Therefore, manually searching 6-mers in 3’UTRs might identify functional sites, 
even when not predicted by sophisticated algorithms. 
 
In the case of miR-409, the target prediction algorithms described binding sites 
that did not seem functional according to the results gathered with 3’UTR reporter 
assays (fig 3.16). In the cell context in use, it could be interesting to identify which 
direct targets of miR-409 are able to cause repression of the β-catenin reporter 
gene. Intriguingly, while being a repressor of the WNT/β-catenin signalling, miR-
409 was described as pathway activator for integrin and c-Met within this 
screening. 
 
With the interconnectivity between these pathways known, it could be extremely 
interesting to dissect further the reciprocal role and define whether the 
upregulation of the other two pathways is indeed related to the WNT signalling 
repression. A proxy for the pathways co-regulation by a single miRNA could be a 
significant PC score after the randomization. Indeed, the score values had 
previously been divided by the amount of proteins within each pathway in order to 
make them comparable. However, no statistical testing to prove that a miRNA is 
significantly co-regulating the three pathways concomitantly was performed, as it 
was deemed unfeasible upon discussion with the collaborating group in 
Göttingen. 
 
These results open again the question on how reliable prediction algorithms are 
when the genome-wide role of a miRNA is only computationally extrapolated. The 
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absence of appropriate prediction of sites which are generally considered less 
functional (e.g. 6mers) could also influence the choice of relevant targets to 
investigate. On the other hand, due to their clear moderate functionality, to take 
into account minor predictions a priori could engulf the results with a myriad of 
false-positives. It is still a very open issue in miRNA biology how to appropriately 
predict miRNA binding sites and it will be interesting to see in the future the 
developments which will be put forward by the scientific community to build more 
reliable models and simplify the search for targets. However, what is still very 
clear is that experimental validation is fundamental to assess the functional 
integration of miRNAs in pathways of interest.  
 
4.7. Is miR-193b involved in a feedback loop with β-catenin? 
Of all miRNAs tested, miR-193b was causing the strongest effects on the WNT/β-
catenin pathway, both in reporter gene and phenotypic assays. Additionally, 
many of the interactions with 3’UTRs of target genes were validated at the 
molecular level. To deepen our understanding of the mechanisms mediated by 
this miRNA, additional target predictions were checked on TS v7. Among the 
genes listed some stood out for their integration within the pathway: WNT 
receptors FZD3 and 8, TCF7L2 (also known as TCF-4), and DKK2. Intriguingly, 
exploring the genomic locus of miR-193b-365a cluster for WNT responsive 
elements, one was found located between the two miRNAs. Therefore, the 
hypothesis that miR-193b-365a cluster could be under transcriptional control of 
the pathway was tested. Analysis of miRNAs expression upon pathway activation 
(recombinant WNT3a stimulation) or repression (iCRT14 treatment) did not show 
any detectable variation (data not shown). Therefore, it seemed that in the cell 
system in use the expression of miR-193b is not under WNT pathway control. 
Still, according to a recent publication, in hepatobiliary cancers WNT induces an 
ultraconserved lncRNA (uc.158-) which is able to bind miR-193b, removing it 
from the available pool and therefore de-repressing its target (Carotenuto, 
Fassan et al. 2017). Due to the inability of WNT to modulate miR-193b 
expression itself, we sought to understand whether in TNBC the WNT pathway 
could regulate the expression of uc.158-, which in turn could affect the other 
miRNA targets. However, in MDA-MB-231 cells, uc.158- was undetectable by 
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qPCR (data not shown), neither in basal condition, nor upon WNT pathway 
activation. Therefore, it was concluded that the mechanism of miR-193b 
sequestration identified in hepatobiliary carcinoma is not established in the cell 
system in use. It remains open whether there are other mechanisms that allow 
the WNT pathway to modulate miR-193b expression or its downstream function, 
therefore creating a possible feedback loop between the two. 
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Supplementary tables and figures 
Due to size limitations, these files are available on the CD version of the thesis 
 
Table 1 
Target protein and corresponding gene names matched with the average 
negative and positive significant FC, amount of significant negative and positive 
interactions, 3’UTR length from TSv7, enrichment results, and validated 
miRTarBase miRNA numbers. 
Table 2 
miRNAs passing the randomisation test. One tab for each pathway. Vec_sign 
values indicates if the miRNA is a repressor (-1) or activator (+1) for the pathway. 
d-values represent the distance between the PC score of the miRNA and the 
average random PC score for the same miRNA after 10’000 randomizations. 
Table 3 
PC score calculated with increasing thresholds in q-value and FC (M value on the 
table). This testing was performed only for the WNT/beta-catenin signalling 
pathway to help for the identification of miRNAs to focus on for functional 
validation. 
Table 4 
q-values and log2FC for the entire RPPA screening, analysed with the limma 
testing by Astrid Wachter.  
Figure 1 and 2 
Heatmaps of moderate t-statistics for Integrin (1) and c-Met (2), including the tree 
of euclidean distance. The name of the targets is listed as the corresponding 
gene name. Please refer to supplementary table 1 for the protein target identifier. 
Figure 3 
Volcano plots of q-values (y-axis) and log2FC (x-axis) for all the targets probed 
within the RPPA screening. Values represented correspond to the ones reported 
in supplementary table 4. 
Figure 4 
c-Met and Integrin signalling pathways are represented as from KEGG pathway 
with colour coding indicative of putative repressive or activating function for each 
protein. 
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